{"title": "Erythropoiesis Stimulating Agents (ESAs) for non-renal disease indications", "author": null, "url": null, "hostname": null, "description": "Use this page to view details for the decision Memo for Erythropoiesis Stimulating Agents (ESAs) for non-renal disease indications (CAG-00383N).", "sitename": null, "date": "2007-03-14", "cleaned_text": "C, Lordick F. platin-based chemotherapy for locally advanced esophagogastric adenocarcinoma: results of a phase II trial. 2006 Gastrointestinal Cancers Symposium:44. Abels R. Use of recombinant human erythropoietin in the treatment of anemia in patients who have cancer. Seminars in Oncology. 1992;19 (No 3 Suppl 8):29-35. Abel R. Erythropoietin for anaemia in cancer patients. Eur J Cancer. 1993;29A(Suppl 2):S2-8. Acs G, Acs P, Beckwith SM, et al. Erythropoietin and erythropoietin receptor expression in human cancer. Cancer Res. 2001;61:3561-5. Acs G, Zhang PJ, Rebbeck TR, Acs P, Verma A. Immunohistochemical expression of erythropoietin and erythropoietin receptor in breast carcinoma. Cancer. 2002;95:969-81. Acs G, Zhang PJ, McGrath CM, et al. Hypoxia-inducible erythropoietin signaling in squamous dysplasia and squamous cell carcinoma of the uterine cervix and its potential role in cervical carcinogenesis and tumor progression. Am J Pathol. 2003;162:1789-806. Adamson JW, Ludwig H. Predicting the hematopoietic response to recombinant human erythropoietin (epoetin alfa) in the treatment of the anemia of cancer. Oncology. 1999;56:46-53. Akizawa T, Kinugasa E, Kitaoka T, Koshikawa S. Effects of recombinant human erythropoietin and correction of anemia on platelet function in hemodialysis patients. Nephron. 1991;58:400-6. Albertsson M. Assessment of quality of life and hemoglobin values in breast-cancer patients treated with epoetin beta. Proc 2002;21:1981. Alcay A, Wun T, Khatri V, Harvey D, Zhou H, White RH. Venous thromboembolism in patients with colorectal cancer: survival. J Clin Oncol. Alexopoulos CG, Ka A. A randomized comparison for cancer related anemia. Ann Oncol. 2004;15 (Suppl 3):page and abstract number not known. American Journal of Kidney Diseases, 37(1)(suppl 1). 2001:p:S210-238. American Society for Clinical Oncology. www.asco.org/portal/site/ASCO. Accessed 4/5/07. American Society of Hematology website. www.hematology.org. 4/5/07. Amgen press release. Available at: Accessed ES, Kessimian N, Levinson R, Steiner M. Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells. Proc Natl Acad Sci U S A. 1990;87:5978-82. Anagnostou A, Liu Z, Steiner M, et al. Erythropoietin receptor mRNA expression in human endothelial cells. Proc Natl Acad H. Circulating platelet-derived microparticles with procoagulant activity may be a potential cause of thrombosis in uremic patients. Kidney Int. 2002;62:1757-64. Ang KK, Berkely B, et al. Impact of epidermal growth factor receptor expression on survival and pattern of relative patients with advanced head and neck carcinoma. Caner Research. 2002;62:7350-6. Antonadou D, Cardamakis E, Puglisi M, Malamos N, Throuvalas N. Erythrpoietin enhances radiation treatment efficacy in patients with pelvic malignancies. Final results of a randomized phase III study. European Journal of Cancer. 2001;37 (Suppl 6):S144. Aoki I, Nishijima K, Homori M, Nakahara Higashi K, Ishikawa K. Responsiveness of bone marrow erythroid progenitors (CFU-E and BFU-E) to recombinant human erythropoietin (rh-Ep) in vitro in multiple myeloma. British Journal of Haematology. Aranesp G, Gikas D, for M, Harris KW, Forget BG. A human erythropoietin receptor gene mutant causing familial erythrocytosis is associated with deregulation of the rates of Jak2 and Stat5 inactivation. Exp Hematol. 1999;27(1):63-74. Arcasoy M, Haroon Z. Expression erythropoietin receptor splice variants in human cancer. Biochem Biophys Amin K, Chou S-C, Haroon Z, Varia M, Raleigh JA. Erythropoietin and erythropoietin receptor expression in head and neck cancer: relationship to tumor hypoxia. Clin Cancer Res. 2005;11:20-27. Arslan Kurt Gonullu G, Demiray M, Kanat O, Manavoglu O. Efficacy of different usage strategies of recombinant human erythropoietin (rHuEPO) in platinum containing chemotherapy. Proc Am Soc Clin Oncol;2002;21:2884. Arslan M, Evrensel Demiray M, Gonullu G, Kanat O, Manavoglu O. Comparison of clinical outcomes of different erythropoietin usage strategies. Tumori. 2004;90:394-8. AuBuchon JP. Managing change to improve transfusion safety. Transfusion. 2004;44:1377-83. Auerbach M, Ballard H, Trout J, McIlwain M, Ackerman A, Bahrain H. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multi-center, open-labeled, Kantarjian H, O'Brien S, Garcia-Manero G, Rios MB, Cortes JE. Use of darbepoetin alfa for the treatment of anemia occurring during imatinib therapy for CML: preliminary evidence of safety and efficacy. Proc Am Soc Clin Oncol. 2003;22:2467. Ayash LJ, Elias A, Hunt M, Demetri G, Wheeler C, Tepler I, Schwartz G, Mazanet R, Reich E, McCauley M, Antman K, Anderson KC. Recombinant human erythropoietin for the treatment of the anaemia associated with autologous bone marrow transplantation. British Journal of Haematology. 1994;87:153-61. Aziz K, Hashem T, Mobarek N, Bary N, Ghoneimy I, Haddad S. Does recombinant human erythropoietin improve the outcome of radiation in head and neck cancer patients? Proceedings of American Society for Therapeutic Radiology And Oncology (ASTRO). 2001;vol.unknown:#2274. Balleari E, Massa G, Marmont A M, Ghio R.. Recombinant Human Erythropoietin for Long-Term Treatment of Anemia in Paroxysmal Nocturnal Hemoglobinuria. Therapy with recombinant erythropoietin in paroxysmal nocturnal haemoglobinuria. Br J Haematol. 1996;94(2):424. Balleari M, Secondo S, Ghio R. Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from 85:174-80. Ehmann WC, Initial dosing of epoetin alfa 60,000 U QW followed by Q2W maintenance for anemic patients with cancer receiving chemotherapy. Journal of Clinical Oncology. 2004;22(14S):8212. Bamias A, Aravantinos D, Pectasides D, Pavlidis N, Fountzilas G. Prevention of anemia in patients with solid tumors receiving platinum based chemotherapy by recombinant human erythropoietin (rHuEpo): a prospective, open label, randomized trial by the Hellenic Cooperative Oncology Group. Oncology. 2003;64:102-10. Barber D, D'Andrea D. Erythropoietin and interleukin-2 activate distinct JAK kinase family members. Mol Cell Biol. 1994;14:6506-14. Barber D, Corless C, Xia K, Roberts T, D'Andrea D. Erythropoietin activates Raf1 by an cells. Blood. Barbone FP, AE, Jolliffe LK, Mulcahy LS. Mutagenesis studies of the human erythropoietin receptor. The Journal of Biological Chemistry. 1997;272(8):4985-92. Baron F, Sautois B, Baudoux E, Matus G, Fillet G, Beguin Y. Optimization of recombinant human erythropoietin therapy after allogenic hematopoietic stem cell transplantation. International Society for Experimental Hematology. 2002; 30:546-554. Baron F, Frere P, Fillet Tandem high-dose therapy (HDT) for multiple myeloma: recombinant human erythropoietin therapy given between first and second HDT allows second peripheral blood stem cell transplantation without red blood cell transfusion. British Journal of Haematology. 20003;123:103-5. Baron F, Frere P, Fillet G, Beguin Y. Recombinant human erythropoietin therapy is very effective after an autologous peripheral blood stem cell transplant when started soon after engraftment. Clinical Cancer Research. 2003;9:5566-72. Barrett-Lee P, Bailey N, O'Brien M, Wager E. Large-scale UK audit of blood transfusion requirements and anaemia in patients receiving cytotoxic chemotherapy. Br J Cancer. 2000;82:93-7. Barrett-Lee P, Ludwig P, Kongable G, Krzakowski M, Schneider M, Schrijvers D, Van Belle S for the European Cancer Anaemia Survey Advisory Board and Participating Centers. Independent risk factors for anemia in cancer patients receiving chemotherapy: results from the European Cancer Anaemia Survey. Oncology. 2006;70:34-48. Barrios M, Alliot C. IgA multiple responding to erythropoietin monotherapy. Am J Hematol. 2005 Oct;80(2):165-6. Barton CM, Hall PA, Hughes CM, Gullick WJ, Lemoine NR. Transforming growth factor alpha and epidermal growth factor in human pancreatic cancer. Journal of Pathology. 1991;163:111-6. Batra S, Perelman N, Luck L, Shimada H, Malik P. Pediatric tumor cells express erythropoietin and a functional erythropoietin receptor that promotes angiogenesis and tumor cell survival. Lab Invest. 2003;83:1477-87. Battaglia A, Fattorossi A, Pierelli L, Ranelletti FO, Coscarella A, De Santis R, Bach S, Mancuso S, Scambia G. The fusion protein MEN 11303 (granulocyte-macrophage colony stimulating factor/erythropoietin) acts as a potent inducer erythropoiesis. Experimental Hematology. 2000;28:490-8. Baz R, Brand C, McGowan Y, Hussein A. High dose recombinant human erythropoietin use is associated with increased overall survival in patients with multiple myeloma. Journal of Clinical Oncology. 2005;23(16S):6621. Beer TM, Higano CS. Darbepoetin administered every 4 weeks for anemia in advanced prostate cancer patients. 2006 Prostate Cancer Symposium. Abstract#2948. Begg T, Hearns J. Components in blood viscosity. The relative contribution of haematocrit, plasma fibrinogen PJ, Strawbridge RR, Hammond S, Van Dyk O, Rigas JR. Fatigue and plasma cytokines in a randomized double-blind placebo-controlled trial of epoetin alfa in patients undergoing combined modality therapy for unrespectable non-small cell lung cancer (NSCLC). 2003;1(Suppl 1):2948. Belenkov A, Shenouda G, Rizhevskaya E, et al. Erythropoietin induces cancer cell resistance to ionizing radiation and to cisplatin. Mol Cancer Ther. 2004;3:1525-32. Bennett CL, Nathan DP, Adams JR. Epoetin alfa use for cancer patients in the United States and Europe: review of vignette and clinical data. Proc Am Soc Oncol. B, N, Tallman MS. Re-importation of pharmaceuticals may be unsafe: lessons learned from the RADAR assessment of erythropoietin (EPO)-associated pure red cell aplasia (PRCA). Journal of Clinical Oncology. 2004:22(14S):2512. Bennett CL, Cournoyer D, Carson KR, et al. Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on adverse drug events and reports (RADAR) project. Blood. 2006;106(10):3343-7. Bergsagel DE, Phil D, Fitzgerald B, Quirt I, Meharchand J, Hasselback R. Treatment of anemia associated with multiple myeloma[Letter to the editor]. The New England Journal of Medicine. 1991;324(1):62. Bern M, Lokich J, Wallach S, Bothe A Jr, Benotti P, Arkin C, Greco F, Huberman M, Moore C. Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial. Ann Intern Med. 1990;112:423-8. Bernell P, Stenke L, Wallvik J, Hippe E, Hast R. A sequential erythropoietin and gm-csf schedule offers clinical benefits in the treatment of anaemia in myelodsyplastic syndromes. Leukemia Research. 1996;20(8):693-9. Besa EC, Kunselman S, Nowell PC. A pilot trial of 13-cis-retinoic acid and alpha-tocopherol with recombinant human erythropoietin in myelodysplastic syndrome patients with progressive or transfusion-dependent anemias. Leukemia Research. 1998; 22:741-9. Bessho M, Jinnai I, Matsude A, Saito M, Hirashima K. Improvement of Anemia by Recombinant Erythropoietin in Patients with Myelodysplastic Syndromes and Aplastic Anemia. International Journal Jinnai Ino H, Tsuji M, Fukuda M, Maruyama M, Kusumoto S, Tominaga K, Matsuda A, Kawai N, Itoh K, Sakata T, Handa A, Endo K, Toyoda A, Kobayashi Y, Kashimura T, Kawano N, Minanihisamatsu M. Trilineage recovery by combination therapy with recombinant human granulocyte colony-stimulating factor and erythropoietin in patients with aplastic anemia and refractory anemia. Stem Cells. 1994;12:604-15. Bessho K, Asano Ikeda Y, Ogawa Tomonaga M, Toyama K, Nakahata T, Nomura T, Mizoguchi H, Yoshida Y, Niitsu Y, Kohgo Y and the Multicenter Study Group. Treatment of the anemia of aplastic anemia patients with recombinant human erythropoietin in combination with granulocyte colony-stimulating factor: a multicenter randomized controlled thrombosis. Piazza D, Cigno A, Carreca I. Reticulocytes can represent and early indicator of the erythropoietic response to darbepoietin alfa in the anemia by chemotherapy. Journal of Clinical Oncology. 2004;22:14S #8245. Birgeg\u00e5rd G, Pere Gasc\u00f3n P, Ludwig H. of anaemia in patients with multiple myeloma and lymphoma:findings of the European Cancer Anaemia Survey. Eur Haematol. Birgeg\u00e5rd S, Schmoll H, Schneider M, D, Shasha D, Van Belle T, Sasse T. Activation of the transcription factor NF-kappa B by the erythropoietin receptor:structural requirements and biological significance. Cell Signal. 2001;13:673-681. Blau AC. Erythropoietin in Cancer: Presumption of Innocence? Stem Cells. 2007;10:1-5. Blayney D, Mirtsching B, Katz D, Tomita D. Every-2-week darbepoetin alfa improves hemoglobin in anemic patients with cancer undergoing chemotherapy: a stratified analysis by tumor type. Blood. 2003;102 Issue 11. Unknown page. Blayney DW, Spiridonidis H, Fesen MR, McGuire WP, Bhatia AW, Hellman RM, Terry D, Tomita D. Darbepoetin alfa every 2 weeks to treat chemotherapy-induced anemia: experience in a Sehouli J, Kimmig R. 6th interim analysis of a prospective, randomized, open and controlled AGO- and NOGGO-intergroup study: sequential adjuvant chemo-radiotherapy with vs without epoetin alfa for pts with high-risk cervical cancer. Proc Am Soc Clin Oncol. H, Kohls A. Results with sequential adjuvant chemo-radiotherapy with vs without epoietin for patients with high-risk cervical cancer: results of a prospective, randomized, open and controlled AGO and NOGGO-intergroup study. Annals of Oncology. 2004;15 (Suppl 3):Page Unknown. Blohmer Dunst J, Harrison L, Johnston P, Khayat D, Ludwig H, O'Brien M, Van Belle S, Vaupel P. Cancer-related anemia: biological findings, clinical implications and impact on quality of life. Oncology. 2005;68(suppl 1):12-21. Blue Cross and Blue Shield Association Technology Evaluation Center (EPC)-Chicago, IL. Seidenfeld J, Piper M, Bohlius J, Weingart O, Trelle S, Engert A, Skoetz N, Schwarzer G, Wilson J, Brunskill S, Hyde C, Bonnell C, Ziegler KM, Aronson N. Comparative effectiveness review number 3. Comparative effectiveness of epoetin and darbepoetin for managing anemia in cancer patients undergoing cancer treatments. Contract No. 290-02-0026. ( [www.effectivehealthcare.ahrq.gov](https://www.effectivehealthcare.ahrq.gov/). Accessed 4/4/07. Copies of the executive summary available via phone call (800) 358-9295 or e-mail ahrqpubs@ahrq.hhs.gov.) Boccia R, Liu D, Silberstein P, Tchekmedyian NS, Holladay C, Tomita D, Rossi G, Otterson G. Evaluating the effectiveness of darbepoetin alfa 300 mcg Q3W for the treatment of chemotherapy-induced anemia. Journal of Clinical Oncology. 2005;23(16S):8129. Boccia R, Malik I, Raja V, Kahanic Lillie T, Tomita D, Clowney B, Silberstein P. Darbepoetin alfa administered every three weeks is effective for the treatment of chemotherapy induced anemia. The Oncologist. 2006;11:409-17. Bohlius J, Langensiepen S, Schwarzer G, Seidenfeld J, Piper M, Bennett C, Engert A. Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis. Journal of the National Cancer Institute. 2005;97(7):489-98. Bohlius J, Weingart O, Trelle S, Engert A. Cancer-related anemia and recombinant human erythropoietin-an updated overview. Nature Clinical Practice Oncology. 2006;3:152-64. Bohlius J, Wilson J, Seidenfeld J, Piper Sandercock J, Trelle O, Bayliss B, Bennett CL, Langensiepen S, Hyde C, Engert A. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst. 2006;98:708-14. Bohlius J, Wilson Seidenfeld Sandercock J, Trelle O, Bayliss S, Djulbegovic B, Langensiepen S, Hyde S, Engert E. Erythropoietin or darbepoetin for patients with cancer: Review. Cochrane Library. John Wiley and Sons. 2007;1-228. www.thecochranelibrary.com J, W, Presnell SR, Cohen FE, Bunn HF. Erythropoietin structure-function relationships. The Journal of K, Hartmann J.-T. Anaemia in cancer patients: pathophysiology, incidence treatment. Journal of Clinical Investigation. 2005;35(suppl 3):26-31. Bokemeyer C, Aapro M, Courdi \u00d6sterborg A, Repetto L, Soubeyran P. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer. 2007 Jan;43:258-70. Epub 2006 Dec 19. Bona R. Thrombotic complications of central venous catheters in cancer Hemost. Epoietin B QOL Working Group. Impact of epoietin B on quality of life in patients with malignant disease. British Journal of Cancer. 2003;88:988-95. Boogaerts M, Oberhoff C, Ten Bokkel Huinink Hayward CRW, Burger HU. Epoetin beta (NeoRecormon\u00ae) therapy in patients with solid tumours receiving and non-platinum chemotherapy: a meta-analysis. Anticancer Pereira J, de Maurino B, Tsujita M, de Souza A, Xavier J, Fock R. Reduction of erythroid progenitors in protein-energy malnutrition. Br J Nutr. 2007;97:307-14. Boschetti, Fermo E, Bianchi P, Vercellati C, Barraco F, Zanella A. Clinical and Molecular Aspects of 23 Patients Affected by Paroxysmal Nocturnal Hemoglobinuria. American Journal of R, Rafanelli D, Longo G, Ferrini PR. Inadequate erythropoietin production in allogeneic bone marrow transplant patients. Haematologica. 1991;76:280-4. Boven K, Stryker S, Knight J, et al. The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes. Kidney International. 2005;67:2346-53. Bowen D, Hyslop A, Keenan N, Groves M, Culligan D, Johnson P, Shaw A, Geddes F, Evans P, Porter J, Cavill I. Predicting erythroid response to recombinant erythropoietin plus granulocytes colony-stimulating factor therapy following a single subcutaneous bolus in patients with myelodysplasia. Haematologica. 2006;91:5:709-10. Boyle P, Robertson C, Kerr DJ. Anemia and neutropenia in cancer patients receiving chemotherapy. Journal of Clinical Oncology. 2004;22(14S):9706. Brocke-Heidrich K, Thiesen HJ, Burger R, Gramatzki M, Horn F. Interleukin-6-dependent gene expression profiles in multiple myeloma INA-6 cells reveal a Bcl-2 family-independent survival pathway closely associated with Stat3 activation. Blood. 2004 Jan 1;103(1):242-51. Epub 2003 Sep 11. Broudy V, Lin N, Brice M, Nakmoto B, Papayannopoulou T. Erythropoietin receptor characteristics on primary human erythroid cells. Blood. 1991;77:2583-90. Bunworasate U, Arnouk H, Minderman H, O'Loughlin K, Sait S, Barcos M, Stewart C, Baer M. Erythropoietin-dependent transformation of myelodysplastic syndrome to acute monoblastic leukemia. Blood. 2001;98:3492-4. Burstein HJ, Parker LM, Keshaviah A, Doherty J, Partridge AH, et al. Efficacy of peglilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy. Journal of Clinical Oncology. 2005;33:20-3. Buyukpamukcu M, Varan A, Kutluk T, Akyuz C. Is epoetin alfa a treatment option for chemotherapy related anemia in children? Medical Pediatric Oncology. 2002;39:455-58. Caillette A, Barreto S, Gimenez E, Labeeuw M, Zech P. Is erythropoietin treatment safe and effective in myeloma patients receiving haemodialysis? Clin Nephrol. 1993;40:176-8. Canadian Orthopedic Perioperative Erythropoietin Study Group. Effectiveness of perioperative recombinant human erythropoietin in elective hip replacement. The Lancet. 1993;341:1227-32. Canon, Vansteenkiste J, Bodoky G, Mateos M, Bastit L, Ferreira I, Rossi G. Final results of a randomized, double-blind, active-controlled trial of darbepoetin alfa administered once every 3 weeks (Q3W) for the treatment of anemia in patients receiving multicycle chemotherapy. Journal of Clinical Oncology. 2005, 23(16S):8284. Carabantes FJ, Benavides M, Trujillo R, Cobo Hebrero ML, Garcia S, Gomez D, Reche P, Breton JJ, Marquez A, Paredes G, Juarez C. Epoetin alfa in the prevention of anemia in cancer patients undergoing platinum-based chemotherapy (CT). A prospective randomized study. 1999 ASCO Annual Meeting:2303. Carlisle R, Hind D, McCabe C, Jones R, Ryan A. Norcom commissioning policy on recombinant human erythropoietin for the treatment of anaemia in people with multiple myeloma and myelodysplastic syndromes. 2004. Carson J, Terrin M, Barton F, Aaron R, Greenburg A, Heck D, Magazinger J, Merlino F, Bunce G, McClelland B, Duff A, Noveck H. A pilot randomized trial comparing symptomatic vs. hemoglobin-level-driven red blood cell transfusions following hip fracture. Transfusion. 1998;38:522-9. Casadevall N, Belanger C, Goy A, Varet B, Lang J, Poisson D. High-dose recombinant human erythropoietin administered intravenously for anti-erythropoietin antibodies in patients treated with epoetin. Nephrol Dial Transplantation. 2003;18(suppl 8):viii37-41. Casadevall Damai Giraudier Dombret Chomienne C, Ribrag V, Stamatoullas A, Marie JP, Vekhoff A, Maloisel F, Navarro R, Dreyfus F, Fenaux P, for the group Myelodysplasies F. Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial. Blood. 2004;104:(2):321-27. Cascinu S, Fedeli A, Del Ferro E, Fedeli S, Catalano G. Recombinant human erythropoietin treatment in cisplatin associated anemia: a randomized double blind trial with placebo. Journal of Clinical Oncology. 1994;12(5):1058-62. Case D, Carey R, Fishkin E, Henry D, Jacobson R, Jones S, Keller A, Craig I, Salmotl R, Silver R, Storniolo AM, Wampler GL, Doole-i CM, Larholt KM, Nelson RA, Abels R. Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy. Journal of the National Cancer Institute. 1993;85(10):801-06. Case AS, Rocconi RP, Barnes MN, Kilgore LC. Comparison of transfusion rates between erythropoietic stimulating agents in gynecologic oncology patients with chemotherapy induced anemia. Journal of Clinical Oncology. 2005;23(16S):5092. Cazzola M, erythropoietin for treatment of refractory anemia in hematologic disorders. Results of a phase I/II clinical trial. Blood. 1992;79(1):29-37. Cazzola M, Messinger D, Battistel Bron V, Spriano M, van Hoof A, Ehmer B. Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-hodgkin's lymphoma: dose finding and identification of predictors of response. Blood. 1995;86(12):4446-53. Cazzola M, Ponchio A, Rovati A, Bergamaschi G, Beguin Y. Prediction of Response to Recombinant Human Erythropoietin (rHuEpo) in Anemia of Malignancy. Haemotolgica. 1996;81-434-41. Cazzola M. Use of recombinant human erythropoietin in anemia of malignancy. Med Oncol. 1998;15 Suppl 1:S1-2. Cazzola M. Haematopoietic myelodysplastic syndromes. Forum. 1999;1:49-57. Cazzola M. Mechanisms of anaemia in patients with malignancy: implications for the clinical use of recombinant human erythropoietin. Medical Oncology. 2000;17(suppl 1):S11-16. Cazzola Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production. British Journal of Haematology. 2003; 122:386-93. Cella D, Evans W, Wallace J, Kallich Blayney D, Vadjan-Raj S. The relationships between FACT-fatigue (FACT-f) scores and physical function (PF) in patients (pts) with chemotherapy-induced anemia treated with darbepoetin alfa (DA). Journal of Clinical Oncology. 2004;22(14S):8062. Cerm\u00e1k J. Erythropoietin administration may potentiate mobilization of storage iron in patients on oral iron chelation therapy. Hemoglobin. 2006;30:105-12. Chakraborty A, Natarajan J, Guilfoyle M, Morgan N, Vercammen E, Cheung W. Population pharmacokinetics of erythropoietin in critically ill subjects. J Clin Pharmacol. 2005;45(2):193-202. Chan A, Leung W, Lin J, Yeo W, Johnson P. Recominant human erythropoietin for anemia in Chinese cancer patients on chemotherapy. The Royal College of Radiologists. 1995;7:272. Chan EM, Comer EM, Brown FC, Richkind KE, Holmes ML, Chong BH, R, Zhang Slovak ML, Willman CL, Noguchi CT, Li Y, Heiber DJ, Kwan L, Chan RJ, Vance GH, Ramsey HC, Hromas RA. AML1-FOG2 fusion protein in myelodysplasia. Blood. 2005;105:4523-6. Chang J, Couture F. A randomized study to evaluate the effects of maintaining hemoglobin levels with epoetin alfa (Eprex) on anemia and quality of life in breast cancer patients receiving myelotoxic chemotherapy. Proc Am Soc Clin Oncol. 2002;21:1502. Chang J, Couture F. Once weekly epoetin alfa maintains hemoglobin, improves quality of life and reduces transfusion in breast cancer patients receiving chemotherapy. Proc Am Soc Clin Oncol. 2003;22:2923. Chang J, Couture F, Young S, McWatters K, Lau C. Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy. J Clin Oncol. 2005;23:2597-2605. Chang J, Phippard L, Sharma D, Lau CY. A phase II randomized trial of three loading doses of epoetin alfa followed by every three-week (q3w) dosing in cancer patients receiving chemotherapy. Journal of Clinical Oncology. 2005;23(16S):8219. Chap L, George M, Glaspy JA. Evaluation of epoetin alfa (Procrit\u00ae) 60,000 U once weekly in anemic cancer patients receiving chemotherapy. Proc Am Soc Clin Oncol. Tomita D, Katz D. A controlled, randomized, open-label study to evaluate the effect of every-2-week darbepoetin alfa for anemia of cancer. Journal of Clinical Oncology. 2004;22(14S):8084. Chester JF, Gaissert HA, Ross JS, Malt RA. in the Syrian hamster induced by N-Nitrosobis (2-oxyopropylO-amine: cocarginogenic effect of epidermal growth factor. Cancer Research. Cheung W, Goon B, Guilfoyle M, Wacholtz M. Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin after single and multiple subcutaneous doses to healthy subjects. Clin Pharmacol Ther. 1998;64:412-23. Cheung W, Natarajan J, Sanders M, Vercammen E. Comparative pharmacokinetics, safety, and tolerability after subcutaneous administration of recombinant human erythropoietin formulated with different stabilizers. Biopharm Drug Dispos. 2000;21(6):211-9. Cheung Pharmacokinetics and pharmacodynamics of epoetin alfa once weekly and three times weekly. Eur J Clin Pharmacol. 2001;57:411-8. Chew H, Wun T, Harvey D, Zhou H, White R. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med. 2006;166:458-64. Chew H, Wun T, Harvey D, Zhou H, White R. Incidence of venous thromboembolism and the impact on survival in breast cancer patients. J Clin Oncol. 2007;25:70-6. Chiba T, Nagata Y, M, Engel JD, Todokoro K. FY. Thromboembolic perioperative chemotherapy in women with early breast cancer: a European organization for research and treatment of cancer breast cancer cooperative group study. Journal of Clinical Oncology. 1994;12(6):1266-71. Clark RE, Smith SA, Jacobs A. Myeloid surface antigen abnormalities in myelodysplasia: relation to prognosis and modification by 13-cis retinoic acid. Journal of Clinical Pathology. 1987;40:652-6. Clavio Balleari R, Gobbi M, Ghio R, Rodgriquez G. Quality of life and brain function following high-dose recombinant human erythropoietin in low-risk myelodysplastic syndromes: a preliminary report. European Journal Cleary SP, Gryfe R, Guindi M, Greig P, Smith L, Mackenzie R, Strasberg S, Hanna S, Taylor B, Langer B, Gallinger S. Prognostic factors in resected pancreatic 2004;198(5):722-31. Cleeland D, Crawford J, Lubeck D, Tomita D. Using the MD Anderson Symptom Inventory (MDASI) to assess symptom burden and interference: interim results of an open-label study of darbepoetin alfa 200 mcg every 2 weeks (Q2W) for the treatment of chemotherapy-induced anemia (CIA). Journal of Clinical Oncology. 2004;22(14S):8065. Cloutier S, Tetu FA, Poulin J, Lau CY, Cantin G. Evaluation of recombinant human erythropoietin (epoetin alfa) and autologous blood donation in breast reconstruction with transverse rectus abdominus myocutaneous (TRAM) flap after Clin Oncol. 2003;22:3106. Coiffier B, Boogaerts M, Kainz C. Impact of epoetin beta versus standard of care on quality of life in patients with malignant disease. 6th Congress of the European Haematology Association. 2001. Abstract #194. Coiffier B, Guastalla J, Pujade-Lauraine E, Bastit T, Anemia Group. Predicting cancer-associated anaemia in patients receiving non-platinum chemotherapy: results of a retrospective survey. Eur J Cancer. 2001;37:1617-23. Coiffier B. Epoetin once weekly in anaemic patients with cancer. British Journal of Haematology. 2004;125:90-102. College of American Pathologists. Special announcement. Notification to all users of practice guidelines. Arch Pathol Lab Med. 2002;126:401. Constantinescu S, Ghaffari S, Lodish F. The erythropoietin receptor: and Bonizzoni E, Gussoni G, Barbui T, Mannucci PM. Incidence of the thrombotic with patients with haematological malignancies with entral venous a 129, 811-17. Cortesi Gascon Milroy R, Pronzato P, Reinhardt U, Shasha D, Thatcher N, Wilkinson P. Standard of care for cancer-related anemia: improving hemoglobin levels and quality of life. 1):22-32. Cortesi E, Marinis F, Orecchia S. Randomized phase III study comparing standard TIW and weekly dosage of epoetin alfa with 2 weeks loading dose: preliminary results. Journal of Clinical Oncology. 2005;23(16S):8215. Crawford J, Blackwell S, Shoemaker D, Pupa M, Sparrow T, Herndon J, Winer E, Flynn J, Dempsey H. Prevention of chemotherapy-related anemia by recombinant human erythropoietin (EPO) in patients with small cell lung cancer receiving cyclophosphamide, doxorubicin, and etoposide (CAE) chemotherapy with G-CSF support. Lung Cancer. 1997;18(1):205. Crawford J, Blackwell S. Erythropoietin and the management of anemia in patients with lung cancer. Cancer Control Journal (supplement);5(2). Crawford J, Robert F, Perry M, Belani C, Sarokhan B. Epoetin alfa 40,000 U once weekly maintains hemoglobin in advanced non-small cell lung cancer patients receiving first-line chemotherapy. Proc Am Soc Clin Oncol. 2003;22:628. Crawford J. protein and Impact of cancer-related fatigue on the lives of patients: new findings from the fatigue coalition. The Oncologist. 2000;5:353-60. D'Ambra M, Gray R, Hillman R, Jones J, Kim H, Rawitscher R, Schnaper H, Szymanski I, Vlahakes G, Kaplan D, Lynch K, Guilfoyle M, Abels R. Effect of recombinant human erythropoietin on transfusion risk in coronary bypass patients. Ann Thorac Surg. 1997;64:1686-93. D'Antonadou C, Skarlatos J, Misailidou D. Darbepoetin alfa improves quality of life in cancer patients undergoing radiation, final results of a multicenter, open study. Journal of Clinical Oncology. 2006;24(18S):18531. Dalton WS. Anemia in multiple myeloma and its management. www.moffitt.org/moffittapps/ccj/v5ns/article9.html. Accessed 5/24/07. Dame C, Fahnenstich Freitag P, Abdul-Nour T, Bartmann P, Fandrey J. Erythropoietin mRNA expression in human fetal and neonatal tissue. Blood. 1998;92:3218-25. Dammacco F, Silvestris Rossi Ferrini P, Caligaris-Cappio F, Pileri A, Resegotti L. The effectiveness and tolerability of epoetin alfa in patients with multiple myeloma refractory to chemotherapy. International Journal Clinical Lab Resources. 1998;28:127-34. Dammacco F, Castoldi G, Rodjer S. Efficacy of epoetin alfa in the treatment of anemia of multiple myeloma. British Journal of Haematology. 2001;113:172-79. Dammacco F, Lucarrelli G, Prete M, Sivlestris F. The role of recombinant human erythropoietin alpha in the treatment of chronic anemia in multiple myeloma. 2002;Suppl 1:32-8. D'Andrea A, Lodish H, Wong G. of the murine erythropoietin receptor. Cell. 1989;57:277-85. D'Andrea A, Jones S. Activation of the erythropoietin receptor stable lymphoid and myeloid transfectants. Dewey MC, Hoffman R. Mechanisms of abnormal erythropoiesis in malignancy. Cancer. 1983;51:1101-6. Dainiak K, Kreczko S. Interactions of insulin, insulinlike growth factor II, and platelet-derived growth factor in erythropoietic culture. J. Clin. Invest. C, Bosneus I, Lundholm K. Protection of metabolic and exercise capacity in unselected weight losing cancer patients following treatment with recombinant erythropoietin: a randomized prospective study. Cancer Research. 1998;58:5374-79. Daneryd P. Epoetin alfa for protection of metabolic and exercise capacity in cancer patients. Seminars in Oncology. 2002;29(suppl 8):69-74. Dang C, Hudis C. Can Granulocyte-Colony Stimulating Factor Worsen Anemia? Journal of Clinical Oncology. 2006;24:2985-6. Danish Head and Neck Cancer Group website Accessed 3/20/07. R, Rudnick S, Abels R. Erythropoietin therapy for anemia associated with AIDS and AIDS therapy and cancer. In MB Garick, Ed. Erythropoietin in clinical applications: An international perspective. New York, NY: Marcel Decker; 1990:301-24. Darbepoetin (Aranesp): 2002 FDA approval letter, phase 4 commitment for study regarding stimulatory effects on metastatic breast cancer. Darbepoetin (Aranesp): 2002 FDA clinical (medical officer) review (redacted). Darbepoetin (Aranesp): 2002 FDA statistical review (redacted). Darbepoetin (Aranesp): (medical officer) review (redacted). Darbepoetin Darbepoetin (Aranesp): 2006 FDA statistical review (redacted). Davis HP. Erythropoietin for patient refusing blood transfusion. Lancet. 1990;336(8711):384-5. De Andrade JR, Jove M, Landon G, Frei D, Guilfoyle M, Young DC. Baseline hemoglobin as a predictor of risk of transfusion and response to epoetin alfa in orthopedic surgery patients. The American Journal of Orthopedics. 1996:533-42. De Campos E, Radford J, Steward W, Milray R, Dougal M, Swindell R, Testa N, Thatcher N. Clinical and in vitro effects of recombinant human erythropoietin in patients receiving intensive chemotherapy for small cell lung cancer. J Clin Oncol. 1995;13(7):1623-31 De Cicco D, Morassut S, Testa V. Central venous thrombosis: an early and frequent complication in cancer patients bearing long-term silastic catheter. A prospective study. Thromb Res. 1997;86:101-13. De Cicco M. The prothrombotic pathogenic mechanisms. Crit Rev Oncol Hematol. De La Chapelle A, Traskelin A, Juvonen E. Truncated erythropoietin receptor causes human erythrocytosis. Proc. Natl. Acad. Sci. 1993;90:4495-99. De Los Santos. threat or opportunity? Gynecologic Oncology. 2007; 105( Aoki K, Park S, Kerwin B. Biophysical comparability of the same protein from different manufacturers: a case study using Epoetin alfa from Epogen and Eprex. J Pharm G, Costantini M, Rosso R. Randomized phase III trial evaluating the role of erythropoietin in the prevention of chemotherapy induced anemia. J Clin Oncol. 1997;15 (Vol 15) 7:2715-21. Del Mastro Donati S. Chemotherapy of non-small-cell lung cancer: role of erythropoietin in the management of anemia. Annals of Oncology. 1999;10(suppl 5). Delarue R, Mounier P, Blanc M, Recher C, Hermine O, Reyes F, Tilly H, Bosly A. Safety of phophylactic use of darbepoetin alfa in patients with diffuse large b-cell lymphoma (DLBCL) treated with R-CHOP 14 GELA study. Blood. 2006;108(11):abstract#2436. Dember LM. Anemia in patients with chronic kidney disease: defining the optimal hemoglobin target (commentary). Nature Clinical Practice Nephrology. 2007;3(5):244-5. Demetri G, Kris M, Wade J, Degas L, Cella D for the Procrit Study Group. Quality of life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. J Clin Oncol. 1998;16:3412-25. Depaoli Lista P, Fo\u00e1 R, Resegotti L. Serum Erythropoietin level and marrow erythroid infiltration predict response to recombinant human erythropoietin in myelodysplastic Haematologica. 1993;78:118-22. Deshmukh N, Tripathi patient receiving therapy. 1995;76:1006-8. Dessypris E, Graber SE, Krantz SB, Stone WJ. Effects of recombinant erythropoietin on the concentration and cycling status of human marrow hematopoietic progenitor cells in vivo. Blood. 1988;72:2060-2. GA, Cacciola RR, Alessi M, Giustolisi R. A good response rate to recombinant erythropoietin alone may be expected in selected myelodysplastic patients. A preliminary clinical study. European Journal of Haemotology. 1996;56:7-11. Di Raimondo F, Azzaro G, Giustolisi R. Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood. Haematologica. 2000;85:800-5. Dicato M, Vercammen E, Liu K, Xiu P, Bowers P. The relationship of body weight and efficacy of fixed dose epoetin alfa vs placebo. Journal of Clinical Oncology. 2005;23(16S):8192. Digicaylioglu M, Bichet S, Marti H. Localization of specific erythropoietin binding sites in defined areas of the mouse brain. Proc Natl Acad Sci USA. 1995;92:3717-20. Dmoszyska A, Kloczko J, Rokicka M, Hellman A, Spicka I, Eid JE. A dose exploration, phase I/II study of administration of continuous erythropoietin receptor activator once every 3 weeks in anemic patients with multiple myeloma receiving chemotherapy. The Hematology Journal. 2007;92(04):493-501. Donati M, Haemostasis. Dong X, in 62:105-118. Duffy JP, Eibl Reber HA, Hines OJ. Influence of hypoxia and neoangiogenesis on the growth of pancreatic cancer. Molecular Cancer. 2003;2:12. Dunphy EP, Petersen IA, Cox RS, Bagshaw MA. The influence of initial hemoglobin and blood pressure levels on results of radiation therapy for carcinoma of the prostate. Int CH, Rodgriquez JJ, McDonough EM, Minster JR, McGrady MD. Erythropoietin reduces anemia and transfusions after chemotherapy with paclitaxel and carboplatin. Cancer. 1997;79(8):1623-8. Dunphy F, Harrison B, Dunleavy T, Rodriguez J, Hilton J, Boyd J. Erythropoietin reduces anemia and transfusions: a randomized trial with or without erythropoietin during chemotherapy. American Cancer Society. 1999;1362-67. Dupont S, Masse A, James C, Teyssandier I, et al. The JAK2 V617F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera. Blood. Pre-published online; March 27, 2007. Dusenbery K, McGuire W, Holt P, Carson L, Fowler J, Twiggs L, Potish R. Erythropoietin increases hemoglobin during radiation therapy for cervical cancer. Int J Radiat Oncol Ratcliffe P, Tan C, Bauer C, Kurtz A. Age-dependent expression of the erythropoietin gene in rat liver and kidneys. J Clin Invest. 1992;89:753-60. Eckardt K, Kurtz A. Regulation of erythropoietin production. Eur J Clin Invest. 2005;35(Suppl. 3):13-9. Economopoulos Stathopoulou E, Pappa M, Raptis S. Treatment of anemia in low risk myelodysplastic syndromes with granulocyte-macrophage colony-stimulating factor plus recombinant human erythropoietin. Leukemia. 1999;13:1009-12. Edwards R, Rickles F, Cronlund M. Abnormalities of blood coagulation in patients with cancer. Mononuclear cell tissue factor generation. J Lab Clin Med. 1981;98:917-28. Elandt K, Horak S, Fischer H, Zielinski CC, Krainer M. Early vs. late treatment with darbepoetin alfa in patients with genitourinary tumors during chemotherapy. Journal of Clinical Oncology. 2006;24(18S):18583. Elbert B, Bunn H. Regulation of the erythropoietin gene. Blood. 1999;94:1864-77. El-Rayes BF , LoRusso PM. Targeting the Epidermal growth Factor Receptor. British Journal of Cancer. 2004;91:418-424. Elliott S, Chang D, Delorme E, Dunn C, Egrie J, Griffin J, Lorenzini T, Talbot C, Hesterberg L. Isolation and characterization of conformation sensitive anti-erythropoietin monoclonal antibodies: effect of disulfide bonds and carbohydrate on recombinant human erythropoietin structure. Blood. 1996;87:2714-22. Erythropoeitin (Procrit): 1993 FDA approval letter, approved labeling, phase 4 commitment for study regarding stimulatory effects on solid tumors. Erythropoeitin (Procrit): 1993 FDA statistical review (redacted). Erythropoeitin (Procrit): 1993 FDA summary basis of approval review (redacted). (No clinical/medical officer review). Erythropoeitin (Procrit): 2004 FDA statistical review of Phase 4 commitment studies for tumor stimulation (redacted). Erythropoeitin (Procrit): 2004 FDA letter indicating completion of phase 4 commitment and Dear Doctor Letter. Erythropoeitin (Procrit): 2004 FDA clinical (medical officer) review (redacted). Erythropoeitin (Procrit): 2004 FDA statistical review clinical pharmacology review FDA review of BEST (redacted). Erythropoeitin (Procrit): 2004 FDA label after review of BEST, Grote, and Henke studies. Erythropoeitin (Procrit): 2004 FDA memo for ODAC meeting. CL, Luminari S. Epoetin-induced pure red-cell aplasia (PRCA): preliminary results from the research on adverse drug events and reports (RADAR) group. Best Practice & Research Clinical Haematology. 2005;18(3):481-9. Falanga A, Gordon SG. Isolation and characterization of cancer procoagulant: a cysteine proteinase from malignant tissue. Biochemistry. Shaw Donati MB, Consonni R, S. Delaini F, Oldani E, Julian JA, Barbui T. The effect of very-low-dose warfarin on markers of hypercoagulation in metastatic Domati M. with malignancy. Int J Hematol. 2001;73:137-44. Falanga A. Clotting mechanisms and cancer: implications in thrombus formation and tumor progression. Clinical Advances in Hematology & Oncology. 2003;1(11):673-8. Falanga A. Thrombosis problem. of Hematology. 2003;88(06):607-10. Falanga A. The effect of anticoagulant drugs on Journal of Thrombosis and vein thrombosis in cancer: the scale of the problem and approaches to management. Annals of Oncology. 2005; 16:696-701. Fallowfield TJ, McNulty P, Gorzegno G, Freund M. Multivariate regression analyses of data from a randomized, double-blind, placebo-controlled study confirm quality of life benefit of epoetin alfa in patients receiving non-platinum chemotherapy. British Journal of Cancer. 2002;87:1341-53. Fandrey J. Oxygen-dependent and tissue-specific regulation of erythropoietin J Physiol Regul Integr Comp Physiol. 2004;286:R977-R988. Faquin W, M. Effect of inflammatory cyokines on hypoxia-induced erythropoietin production. Blood. 1992;79:1987. Faris PM, Ritter MA, Abels RI. The effects of recombinant human erythropoietin on perioperative transfusion requirements in patients having a major orthopaedic operation. The Journal of Bone and Joint Surgery. 1996;78(1):62-72. Farrell F, Lee A. The erythropoietin receptor and its expression in tumor cells and other tissues. Oncologist. 2004;9 (Suppl 5):18-30. Faulds D, Sorkin E. Epoietin erythropoietin). A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in anemia and the stimulation of erythropoiesis. Drugs. 1989;38:863-99. Fastenau J, Lefebvre P, Duh MS, Buteau S, McKenzie RS, Piech CT. Evaluation of the relationship between early hemoglobin rise during epoetin alfa treatment and improved patient-reported quality of life. Journal of Clinical Oncology. 2004;22(14S):8124. Faust E. A phase III, double-blind, placebo-controlled, randomized study of novel erythropoiesis stimulating protein (Aranesp) in patients undergoing platinum-treatment for lung Proc Am Soc Clin Oncol. 2001;20:1293. Fastenau J, Memisoglu A, Peake C, Salva C, Howell J, McKenzie S. Dosing and outcomes study of erythropoiesis-stimulating therapies-D.O.S.E. Journal of Clinical 2005;23(16S):6092. Smith FC, Whitsitt P, Wheeler SL, Lau CY. Erythropoietin with iron supplementation to prevent allogeneic blood transfusion in total hip joint arthroplasty. Annals of Internal Medicine. 2000;133:845-54. Feffer S, Carmosino L, Fox R. Acquired protein C deficiency in patients with breast cancer receiving cyclophosphamide, methotrexate, and 5-fluorouracil. Cancer. 1989;63:1303-7. Fein D, Lee W, Hanlon A, Ridge J, Langer C, Curran W Jr, Coia L. Pretreatment hemoglobin level influences local control and survival of T1-T2 squamous cell carcinomas of the glottic Sytkowski AJ. Erythropoietin stimulates growth and STAT5 phosphorylation in human prostate epithelial and prostate cancer cells. The Prostate. 2006;66:135-45. Finelli EV, Bosi Rondoni M, Baccarani M. High doses of recombinant erythropoietin alfa for myelodysplastic syndromes: high incidence of responses in patients with low pre-treatment serum erythropoietin concentrations. Journal of Clinical Oncology. 2004;22(14S):6683. Fischl M, Galpin J, Levine J, Groopman J, Henry D, Kennedy P, Miles S, Robbins W, Starrett B, Zalusky R. Recombinant human erythropoietin for patients with AIDS treated with zidovudine. N Engl J Med. 1990;322:1488-93. Fisher B, Redmond C, Legault-Poisson S, Dimitrov V, Brown M, Wickerham D, Wolmark N, Margolese R, Bowman D, Glass A. Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel Project B-16. J Clin Oncol. 1990;8:1005-18. Fraser J, Lin F, Berridge M. Expression of high affinity receptors for erythropoietin on human bone marrow cells and on the human erythroleukemic cell line, Exp Hematol. 1988;16:836-42. Fraser J, Tan A, Lin F, Berridge M. Expression of specific high-affinity binding sites for erythropoietin on rat and mouse megakaryocytes. Exp Hematol. 1989;17:10-6. Fried W, Ward HP, Hopeman AR. Leiomyoma and erythrocytosis: a tumor producing a factor which increases erythropoietin production. Report of case. Blood. 1968;31(6):813-6. Frolove A, Schuller K, Tzeng CD, Cannon EE, et al. ErbB3 expression and dimerization with EGFR influence pancreatic cancer cell et al. Pharmacokinetics and pharmacodynamics of Tamura T, Ohe Yamamoto N, Nokihara H, Horiike A, T, Saijo N. Pharmacokinetics and pharmacodynamics of weekly epoetin in cancer J Oncol. J, Cleeland C, Livingston R, Sarokhan B, Winer E, Einhorn L. Clinical evaluation of once weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three times weekly dosing. J Clin Oncol. Tomita D, Colowick A. Assessment of symptom burden using the MD Anderson Symptom Inventory (MDASI) in subjects with nonmyeloid malignancies receiving multicycle chemotherapy and darbepoetin alfa Soc R, Mushtag C, Sekeres M, Lam H, Dreiling L. The efficacy and safety of darbepoetin alfa for testing anemia in low-risk myelodysplastic syndrome patients: results after 53/55 weeks. Blood. J, Paquette R, Lyons R, Mushtag C, Sekeres M, Lam H, Dreiling L. Darbepoetin alfa for treatment anemia in patients with low-risk myelodysplastic syndromes: exploratory analysis of baseline predictors of response. Journal of Clinical Oncology. 2006;24:20(18S):6579. Gagnon D, Zagari M. Assessing the clinical significance of health-related quality of life (HrQOL) improvements in anaemic cancer patients receiving epoetin alfa. Eur J Cancer 2003;39:335-345. Galli M, Elice F, Crippa C, Comotti B, Rodeghiero F, Barbui T. Recombinant human erythropoietin and the risk of thrombosis in patients receiving thalidomide for multiple myeloma. A, Giannarell D, Callabresi F. Erythropoietin for the prevention of anaemia in neoplastic patients treated with cisplatin. Eur Vol 29A (Suppl 2):S13-14. Ganser A, Ottmann OG, Hoelzer D. Interleukin-3 in the treatment of myelodysplastic syndromes. International Journal of Clinical & Laboratory Research. 1992;22:125-8. Ganser A, Hoelzer D. Clinical use of hematopoietic growth factors in the myelodysplastic syndromes. Seminars Garton J, Gertz M, Witzig T, Greipp P, Lust J, Schroeder G, Kyle R. Epoetin alfa for the treatment of the anemia of multiple myeloma: a prospective, randomized placebo-controlled, double-blind trial. Archives Internal Medicine. 1995;155:2069-74. Gascon P, Barrett-Lee PJ. Prevalence of anemia in cancer patients not receiving antineoplastic treatment (ANT): data from the European cancer anaemia survey Journal of Clinical Oncology. 2006; 24(18S):8565. Gascon B, Ludwig H. Evaluation of anaemia in patients with multiple myeloma and lymphoma: findings of the European Cancer Anaemia Survey. European Journal of Haematology. 2006;77:378-86. Ghio R, Balleari E, Ballestrero A, Gatti AM, et al. Subcutaneous recombinant human erythropoietin for the treatment of anemia in syndromes. Tormo M, Navarro P, Benedit P, Gasquet JA. Darbepoetin a for the treatment of anemia in patients with myelodysplastic syndromes. Cancer. Jadeja Justice G, Kessler J, Richards D, Schwartzberg L, O'Byrne J, Armstrong S, Colowick A. Randomized, active-controlled, phase \u00bd, dose-escalation study of NESP administered weekly and every 2 weeks in patients with solid tumors. Proc Am Soc Clin Oncol. 2001;20:1546. Glaspy J, G, 2000174 Study Group, Fleishman A, Armstrong S, Colowick A. Optimizing the management of anemia in patients with cancer: a randomized, active-controlled study investigating the MH, Kallich J. Early and sustained improvement in health-related quality of life (HRQOL) was observed with frontloaded darbepoetin alfa compared to conventional therapy. Proc Am Soc Clin Oncol. 2003;22:3063. Glaspy J, Berg R, Tomita D, Rossi G, Vadhan-Raj S. Final results of a phase 3, randomized, open-label study of darbepoetin alfa 200 mcg every 2 weeks (Q2W) versus epoetin alfa 40,000 U weekly (QW) in patients with chemotherapy-induced anemia (CIA). Journal of Clinical Oncology. 2005 ASCO Annual Meeting Proceedings, 23(16S):8125. Glaspy J, Henry D, Canon J, Lam H, Lillie T. Darbepoetin alfa administered at varying intervals compared with weekly epoetin alfa for treating chemotherapy-induced anemia: a pooled analysis of 20 clinical trials. Journal of Clinical Oncology. 2006;24(18S):18508. Glaser C, Millesi W, Wanschitz F, Schull B, Lang S, Leitha T. R-Hu Erythropoeitin treatment increases efficacy of neo-adjuvant radiochemotherapy and improves cancer free survival of patient with oral squamous cell carcinoma: a 17 months follow-up. 1999 ASCO Annual Meeting:abstract #1543. Glaser C, G, S, B, Watzinger, Christoph F, Lang S, Selzer E, Lavey R. Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of pre-operative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharyyx. Int J Rad Oncol Biol Physics. 2001;50:705-15. Glaspy J, Bukowski R, Steinberg D, Taylor C, Tchekmedyion S, Vadhan-Raj S for the Procrit Study Group. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Journal of Clinical Oncology. 1997;15:1218-34. Glaspy J, Singh J, Justice G, Kessler J, Richards D, Schwartzberg L, Rigas J, Kuter D, Harmon D, Prow A, H, Boccia R, O'Byrne J, Colowick A. A dose-finding and safety study of novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia in patients receiving multicycle chemotherapy. British Journal of Cancer. 2001;84 (1):17-23. Glaspy J, Degos L, Dicato M, Demetri G. Comparable efficacy of epoetin alfa for anemic cancer patients receiving platinum and nonplatinum-based chemotherapy: a retrospective subanalysis of two large, community-based trials. The Oncologist. 2002;7:126-35. Glaspy J, Jadeja J, Justice G, Kessler J, Richards D, Schwartzberg L, Tchekmedyian N, Armstrong S, O'Byrne J, Rossi G, Colowick A. Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy. British Journal of Cancer. 2002;87:268-76. Glaspy J, Jadeja J, Justice G, Fleishman A, Rossi G, Colowick A. A randomized, active-control, pilot trial of front-loaded dosing regimens of darbepoetin-alfa for the treatment of patients with anemia during chemotherapy for malignant disease. Cancer. 2003;97 (5):1312-20. This is the webcast presentation of the terminated darbpoetin study: Glaspy J. Results from a Phase III, randomized, double-blind, placebo-controlled study of darbepoetin alfa (DA) for the treatment of anemia in patients not receiving chemotherapy or radiotherapy. Phase III Clinical Plenary Session: Breakthroughs in Clinical Research (Clinical Research Track: Special Session 1) American Association for Cancer Research Annual Meeting 2007 4/16/07 8:15 AM-10:15 AM www.acr.org/home/scientists/meetingsworkshops/annual-meeting-2007/webcast-sessions.aspx. Accessed 4/18/07. Glimelius B, Linne Hoffman Larsson Svensson J, Nasman P, Svensson B, Helmers C. Epoetin beta in the treatment of anemia in patients with advanced gastrointestinal cancer. J Clin Oncol. 1998;16(2):434-40. Glossmann J, Engert Rudolph C, Metzner B, Dorken B, Wiedenmann S, Diehl V, Josting A. Recombinant human erythropoietin, epoetin beta, in patients with relapsed lymphoma treated with aggressive sequential salvage chemotherapy\u2014results of a randomized trial. Ann Hematol. 2003;82:469-75. Goldberg M, Schneider T. Similarities between the Oxygen-sensing Mechanisms Regulating the Expression of Vascular Endothelial Growth factor and Erythropoietin. The Journal of Biological Chemistry. 1994; 269:4355-4359. Goldberg M, McCutchen JW, Jove M, DiCesare P, Friedman RJ, Poss R, Guilfoyle M, Frei D, Young D. A safety and efficacy comparison study of two dosing regimens of epoetin alfa in patients undergoing major orthopedic surgery. The American Journal of Orthopedics. 1996;544-52. Goldberg P. Study finds more deaths on Aranesp arm in cancer anemia study, no benefit seen [newsletter]. The Cancer Letter. 2007;33:1. Goldstein D, Carroll S, Apte M, Keogh G. Modern management of pancreatic carcinoma. Intern Med J. 2004;34(8):475-81. Goodnough LT. Risks of Blood Transfusion. Anesthesiology Clin N Am. 2005;23:241-52. Goy A, Belanger F, Guesnu M, Jaulmes D, Poisson D, Varet B. High doses of intravenous recombinant erythropoietin for the treatment of anaemia in myelodysplastic syndrome. British Journal of Haematology. 1993;84:232-7. Grandis JR, Drenning S, Xhakraborty A, Zhou M, Zeng QPitt A, Tweadry D. Requirement of Sta3 but not Stat 1 Activation for Epidermal Growth Factor Receptor-mediated Cell Growth In Vitro. Journal of Clinical Investigation. 1998;102:1385-1392. Grandis JR, Drenning SD, Zeng Q, Watkins SC, Melhem MF, Endo S, Johnson DE, Huang L, He Y, Kim JD. Constitutive activation of Stat3 F, Porrozzi S, Gasparini G, Matovani G. Comparing the efficacy and safety of fixed versus weight-based dosing of epoetin in anemic cancer patients receiving platinum-based chemotherapy. Oncology Reports. 2003;10:1289-96. Greenspan E. Treatment of anemia associated with multiple myeloma[Letter to the editor]. The New England Journal of Medicine. 1991;324(1):62. Grignani G, Falanga A, Pacchiarini L, Alessio MG, Zucchella M, Fratino P, Donati MB. Human breast and colon carcinomas express cysteine proteinase activities with pro-aggregating and pro-coagulant J. 1988;42:554-7. Groopman J, Itri L. Chemotherapy-induced anemia in Langer D. alfa 60,000 U QW followed by 80,000 U Q3W maintenance in patients with anemia and cancer receiving chemotherapy. Journal of Clinical Oncology. 2004;22(14S):8215. Gross J, Moller R, Henke W, Hoesel W. Detection of anti-EPO antibodies in human sera by a bridging ELISA is much more sensitive when coating biotinylated rhEPO to streptavidin rather than using direct coating of rhEPO. Journal of Immunological Methods. 2006;313:176-82. Grossi G, Pagliai G, Ferrini PR. Erythropoietin upregulates the expression of its own receptor in tf-1 cell line. Leukemia Research. 1998;22(2):145-51. Grossi A, Fabbri A, Santini V, Leoni F, Nozzoli Longo G, Pagliai G, Ciolli S, Fishkin E, Henry D, DeLeo M, Fink K, Sullivan D. Efficacy and safety analysis of epoetin alfa in patients with small-cell lung Fayers SP. Quality of life may be affected more by disease parameters and response to therapy than by haemoglobin changes. Eur J Haematol. 2005;75:293-8. Gussetis ES, Peristeri J, Kitra V, Liakopoulou T, Kattamis A, Graphakos S. Clinical value of bone marrow cultures in childhood pure red cell aplasia. Journal of Pediatric Hematology/Oncology. 1998; 20(2):120-124. Haematoloica. Editorial, comments & news. 2003;88(06):601-5. Hallahan D, Chen A, Teng M, Cmelac A. Drug-radiation interactions in tumor blood vessels. Oncology (Williston Park). 1999 Oct;13(Suppl 5):71-7. Halstenson C, Macres M, Katz S, Schneiders J, Watanabe M, Sobota J, Abraham P. Comparative pharmacokinetics and pharmacodynamics Ralfkiaer E. Recombinant human granulocyte-macrophage colony-stimulating factor plus recombinant human erythropoietin may improve anemia in selected patients with myelodysplastic syndromes. American Journal of Hematology. 1993;44:229-36. Hansen O, Baekke J, Hansen KH, Peter S. The need of transfusion of packed red blood cells in pallitative chemotherapy for advanced NSCLC when no erythropoietin is used. Proc Am Soc Clin Oncol. 2003;22:2817. Hardee M, Arcsoy M, Blackwell K, Kirkpatrick J, Dewhurst M. Erythropoietin biology in cancer. Clin Cancer Res. 2006;12:332-9. Hardee M, Kirkpatrick J, Shan S, Snyder S, Vujaskovic Z, Rabanni Z, Dewhirst M, Blackwell K. Human recombinant erythropoietin (rEpo) has no effect on tumor growth or angiogenesis. Br J Cancer. 2005;93:1350-5. Harman C. What new drugs can nephrologists look forward to in the next year or two? Nature Clinical Practice Nephrology. 2007;3(5):235. Harris K, Winkelmann J. Enzyme-linked immunosorbent assay detects a potential soluble form of the erythropoietin receptor in human plasma. Am J Hematol. 1996;52:8-13. Haroon Z, Amin K, Jiang X, Arcasoy M. A novel role for erythropoietin during fibrin-induced wound-healing response. Am J Pathol. 2003;163:993-1000. Harrison L, Shasha D, Horel P. Prevalence of anemia in cancer patients undergoing radiotherapy:prognostic significance and treatment. Oncology. 2002;63(Suppl Long-term follow-up of 18 patients with myelodysplastic syndromes responding to recombinant erythropoietin treatment. Leukemia Research. 2001;25:13-18. Heaney ML, Golde DW. Myelodysplasia. New England Journal of Medicine. 1999;340:1649-1660. Hedenus M, Hansen S, Taylor K, Arthur C, Emmerich B, Dewey C, Watson D, Rossi G and Osterborg O on behalf of the Darbepoetin alfa 990114 Study Group. Randomized, dose-finding study of darbepoetin alfa in British Journal of Haematology. 2002;119:79-86. Hedenus M, Adriansson M, San Miguel J, Kramer M, Schipperus M, Juvonen E, Taylor K, Belch A, Alte\u00b4s A, Martinelli G, Watson D, Matcham J, Rossi G and Littlewood T on behalf of the Darbepoetin alfa 20000161 Study Group. Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: J, Kotasek D, Austin M, RG. Darbepoetin alfa for the treatment of chemotherapy-induced anemia: disease progression and survival analysis from four randomized, double-blind, placebo-controlled trials. Journal of MD, Mohr DN, Melton III J. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism. Arch Intern Med. 2002;162:1245-8. Hellstrom-Lindberg E, Birgegard G, Lockner D, Helmers C, Ost A, Wide L. Treatment of myelodysplastic syndromes with recombinant human erythropoietin. Eur J Haematol. 1991;47:355-60. Hellstrom-Lindberg E, Birgegard G, Carlsson I, Grimfors G, Merk K, Tangen J, Winqvist I, Ost A. A combination of granulocyte colony-stimulating factor and erythropoietin may synergistically improve the anaemia patients with myelodysplastic syndromes. Leukemia and Lymphoma. 1993;11:221-8. Hellstorn-Lindberg E. Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies. British Journal of Haematology. 1995;89:67-71. Hellstr\u00f6m-Lindberg E, Kanter-Lewensohn L, \u00d6st A. Morphological changes apoptosis in bone marrow from patients with myelodysplastic syndromes treated with granulocyte-csf and erythropoietin. Leukemia Research. 1997;21:415-425. Hellstrom-Lindberg E, Negrin R, Stein R, Krantz S, Lindberg G, Vardiman J, Ost A, Greenberg P. Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive mode. British Journal of Haematology. 1997;99:344-51. Hellstrom-Lindberg E, Ahlgren T, Beguin J, Winqvist I, Oberg G, Osterborg A, Ost A. Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients. American Society of Hematology. 1998;92(11):68-75. Hellstr\u00f6m-Lindberg E, Gulbrandsen N, Lindberg JM, Winquist I, Wisloff F. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. British Journal of Haematology. 2003;120:1037-46. Henke M, Guttenberger R, Barke A, Pajonk F, Potter R, Fr\u00f6mmhold H. Erythropoietin for patients undergoing radiotherapy: a pilot study. Radiotherapy and Oncology. 1999;50:185-90. Henke R, Rube C, Schafer U, Haase K, Schilcher B, Mose S, Beer K, Burger U, Dougherty C, Frommhold H. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, Bezay C, Weissenberger C, Werner M, Pajonk F. Do erythropoietin receptors on cancer cells explain unexpected clinical findings? J Clin Oncol. 2006;24:4708-13. Henry D, Abels R. Prediction of response to recombinant human erythropoietin therapy in cancer patients. 1994; 21(2 Supp 3):21-8. Henry D, Brooks B, Case D, Fishkin E, Jacobson R, Keller A, Kugler J, Moore J, Silver R, Storniolo A, Abels R, Gordon D, Nelson R, Larholt K, Bryant E, Rudnick S. Recombinant human erythropoietin therapy for anemic cancer patients receiving cisplatin chemotherapy. The Cancer Journal from Scientific American. 1995; April:252-60. Henry D, Patel R, Tchekmedyian S, Jumbe N, Austin M, Berg R, Allen C, Glaspy J. A phase 2 randomized study evaluating the timing of darbepoetin alfa administration relative to chemotherapy. Proc Am Soc Clin Oncol. 2003;22:3162. Henry DH, Kamin M, Wilhelm F, Williams D, Xie J, Woodman RJ. Final results of a randomized study comparing two dosing regimens of epoetin alfa in patients with chemotherapy-induced anemia: 80,000 U every two weeks vs 40,000 U weekly. Journal of Clinical Oncology. 2006;24(18S):8624. Henze G, Michon J, Morland A. Phase III randomized study: efficacy of epoetin alfa in reducing blood transfusions in newly diagnosed pediatric cancer patients receiving chemotherapy. Proc Am Soc Clin Oncol. 2002;21:1547. Heras P, Hatzopoulos A, S. Efficacy and safety of epoetin beta 30,000 IU once weekly in patients with solid tumors and chemotherapy-induced anemia. Journal of Clinical Oncology. 2006;24(18S):18620. Herrmann F, Mertelsmann R, Lindemann A, Ottman OG, Seipelt G, Oster W, Hoelzer D, Ganser A. Clinical use of recombinant human hematopoietic growth factors (GM-CSF, IL-3, EPO) in patients with myelodysplastic syndrome. Biotechnology Therapeutics. 1991;2(3&4):299-311. Herrington J, Davidson S, Tomita D, Green L, Smith R, Boccia R. Utilization of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia. Am J Health Syst Pharm. 2005;62(1):54-62. Hesketh PJ, Arena F, Patel D, D'Avirro P, Rossi G, Schwartzberg L. Front-loaded darbepoetin alfa with Q3W maintenance administered as a fixed or weight-based dose in anemic cancer patients results in similar efficacy profiles. Proc Am Soc Clin Oncol. 2003;22:2941. Hesketh J, Arena F, Patel D, Austin M, D'Avirro P, Rossi G, Colowick A, Schwartzberg L. A Randomized controlled trial of Darbepoetin Alfa administered as a fixed or weight-based dose using a front-loading schedule in patients with anemia who have nonmyeloid malignancies. American Cancer Society. 2004;100(4):859-68. Hirashima K, Bessho M, Jinnai I. Improvement in anemia by recombinant human erythropoietin in patients with myelodysplastic syndrome and aplastic anemia. Contributions to Nephrology. 1991;88:254-65. Hitomi Fujita Y, Ichiba S, Takahashi T, Imura H. Erythropoietin receptor of a human leukemic cell line with erythroid characteristics. Biochemical and 1988;154(3):902-9. Amelsvoort MP, Broeders L, van der Plas DC, van Lom K, Hoogerbrugge H, Touw IP, L \u00f6wenberg B. Erythropoietin-induced activation of STAT5 is impaired in the myelodysplastic syndrome. Blood. 1997;89(5):1690-1700. Homoncik M, Jilma-Stohlawetz P, Erythropoietin increases platelet reactivity and platelet counts in patients with alcoholic P, Bunn HF. Cadmium and platinum suppression of erythropoietin production in cell culture: Clinical implications. Blood. 2000;96:3743-7. Hoshino S, Teramura Motoji T, Oshimi K, Ueda M, Mizoguchi H. Expression and characterization of erythropoietin receptor s on normal human bone marrow cells. International Journal of Cell Cloning. 1989;7:156-7. Huddart R, Welch R, Chan S, Perren T, Atkinson R. A prospective, randomised trial comparative-group evaluation of epoetin alfa for the treatment of anaemia in UK in cancer patients receiving platinum-based chemotherapy. Annals of Oncology. 2002;23:177. Hudis C, Williams D, Gralow J. Epoetin alfa maintains hemoglobin levels and quality of life in breast cancer patients during adjuvant chemotherapy. Proc Am Soc Clin Oncol. 2002;21:1518. Hudis C, Williams D, Gralow JR. Epoetin alfa maintains hemoglobin and quality of life in breast cancer patients receiving conventional adjuvant chemotherapy: final report. Proc Am Soc Clin Oncol. Tanguy-Schmidt Francois S, Gardembas-Pain M, Dib M, Foussard before high-dose therapy allows autologous peripheral stem-cell transplantation without red blood cell transfusion: a pilot study. Bone Marrow Transplantation. 2005;35:903-7. Hussein MM, Mooij JMV, Roujouleh H. Use of recombinant erythropoietin in the treatment of anaemia associated with multiple myeloma in a haemodialysis patient. Nephrology Transplantation Koutras A, Rigopoulos A, Vagenakis A, Kalofonos H. Effects of recombinant human erythropoietin on quality of life in cancer patients receiving chemotherapy: results of a randomized, controlled trial. Journal of Pain and Symptom Management. 2003;(Vol 25);6:512-18. Ikegaya N, Yamamoto T, Takeshita A, Watanabe Miyaji T, Ohishi K, Furuhashi M, Maruyama Y, Hishida A. Elevated erythropoietin receptor and transforming growth factor-\u00df1 expression in stenotic arteriovenous fistulae used for hemodialysis. J Am Soc Nephrol. Imamura M, Kobayashi M, Kobayashi S, Yoshida Ishikawa Y, Matsumoto T, Okuno A, Maekawa I, Sakurada K, Miyazaki T. Failure of combination therapy with recombinant granulocyte colony-stimulating factor and erythropoietin in myelodsyplastic syndromes. Annals of Hematology. 1994;68:163-6. Imamura M, Kobayashi Yoshida Ishikawa Y, Matsumoto T, Okuno A, Maekawa I, Sakurada K, Miyazaki T. Combination therapy with recombinant human granulocyte colony-stimulating factor and erythropoietin in aplastic anemia. Sereno M, Perona R, Baron MG. Erythropoietin receptor expression in bladder cancer. Journal of Clinical Oncology. 2006;24(18S):4584. Inomata Y, Hirata A, Takahashi E, Kawaji T, M, Tanihara H. Elevated erythropoietin in vitreous with ischemic retinal diseases. Clinical Neuroscience and Neuropathology. J, Woler M, Gorin N, Bauters F. Efficacy of recombinant human erythropoietin in the treatment of refractory anemias without excess of blasts in myelodysplastic syndromes. Leukemia and Lymphoma. 1994;12:307-14. Italian Cooperative Study Group. A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in low-risk myelodysplastic syndromes. Journal of comparison of U QW vs darbepoetin alfa 200 mcg Q2W in anemic patients with cancer receiving chemotherapy: preliminary results. Blood. 2003;102(11):4391. J\u00e4dersten M, Montgomery SM, Dybedal I, Porwit-MacDonald A, Hellstr\u00f6m-Lindberg. Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF. Blood. 2005;106:803-11. James C, Ugo V, Casadevall N, A JAK2 mutation in myeloproliferative disorders: pathogenesis and therapeutic and scientific prospects. Trends in molecular medicine. 2005;11(112):546-54. Janinis J, Dafni U, Aravantinos of life (QOL) outcome of epoietin-alpha (EPO-A) in anemia cancer patients undergoing platinum or non-platinum-based chemotherapy: a randomized study conducted by the Hellenic Group. Proc Am Soc Clin Oncol. 2003;22:789. .Jelic S. Management of hematological complications of malignancy and chemotherapy: the role of hematopoietic growth factors. Arch Oncol. 2004;12(3):177-8. Jelkmann A. The role of the liver in the production of thrombopoietin compared with erythropoietin. Eur J Gastroenterol Hepatol. 2001;13:791-801. Jitnuyanont A. Impact of therapy with recombinant human erythropoietin (r-HuEPO) and quality-of-life in anemic cancer patients. Intern Med J Thai. 2001;17:283-290. Johansson J, Wersa P, Brandberg Y, Andersson S, Nordstrom L and the EPO-Study Group. Efficacy of epoetin beta on hemoglobin, quality of life, and transfusion needs in patients with anemia due to hormone-refractory prostate ancer: a randomized study. Scand J Urol Nephrol. 2001;35:288-94. Jones S, D'Andrea A, Haines L, Wong G. Human erythropoietin receptor: cloning, expression, and biologic characterization. Blood. 1990;76:31-5. Jumbe NL, Heatherington AC. Darbepoetin alfa rational dose/schedule evaluation based on quantitative understanding of erythropoiesis for early and sustained alleviation of anemia. Proc Am Soc Clin Oncol. 2003;22:abstract 3077. Justice Poulsen E, Jumbe darbepoetin anemia. Oncol. JF, Jadeja J, Campos L, Weick J, Chen CF, Heatherington AC, Amado RG. A randomized multicenter study of subcutaneous and intravenous darbepoetin alfa for the treatment of chemotherapy -induce anemia. Annals of Oncology.2005;16:1192-1198. Kagan A, Sinay-Trieman L, Bar-Khayim Y. Recombinant human erythropoietin for anaemia in thalassaemia minor patients on dialysis[Letter to the Dialysis Transplantation. 1995;10(12):2375-6.. Kajikawa T, Kurokawa Hashimoto S, Harada A, Nakao A, Takagi H. Autologous Blood Transfusion for Hepatectomy in Patients with Cirrhosis and Hepatocellular Carcinoma: Use of Recombinant Human Erythropoietin. Surgery. 1994;115:727-34. Kakkar A, DeRuvo N, Chinswangwatanakul V, Tebbutt S, Williamson R. Extrinsic-pathway activation in cancer with high factor VIIa and tissue factor. Lancet. 1995 ;346:1004-5. Kallich J, Erder H, Glaspy JA, Tchekmedyian S. Darbepoetin alfa has higher observed improvements in fatigue and physical well-being than epoetin alfa. Proc S, Grandis R. Epidermal growth factor receptor biology in head and neck cancer. Journal of Clinical Oncology. 2006;24(17):2666-72. Kanoh T, Fujii H. Phagocytic myeloma cells. Report of a case and review of the literature. Am J Clin Pathol. 1985;84(1):121-4. Kasper Seeber S, Nowrousian MR. Recombinant human erythropoietin in the treatment of cancer-related anaemia. European Journal of Heamotology. 1997;58:251-6. Kasper C, Zahner J, Sayer HG. Recombinant human erythropoietin in combined treatment with granulocyte- or granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes. Journal of Research and Clinical Oncology. AG, Orth DN, Gray localization of human epidermal growth factor/urogastrone in several human tissues. The Journal of Histochemistry and Cytochemistry. 1985;33(4):315-22. Katodritou M, Christakis J. Evaluation of hypochromic erythrocytes in combination with s TfR-F index for predicting response to r-HuEPO in anemic patients with multiple myeloma. Laboratory Hematology. 2006;12:47-54. Kaufman S, Reda J, Fye C, Goldfarb D, Henderson W, Kleinman J, Vamone C. Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemodialysis Patients. N Engl J Med. 1998;339:578-83. Kessler C. Anticoagulation and thrombolytic therapy. Practical considerations. Chest. 1989;95(5 Suppl):245S-56S. Kirito K, Nakajima K, Watanabe T, Uchida M, Tanaka M, Ozawa K, Komatsu N. Identification of the human erythropoietin receptor region for Stat1 and Stat3 activation. Blood, 1 January 2002, Vol. 99, No. 1, pp. 102-110. factor human cancer. A, Jernberg-Wiklund H, Mellstedt H, \u00d6sterborg A. Expression of erythropoietin receptor and In vitro functional effects of epoetins in B-cell malignancies. Clin Vlla complex: clinical significance, structure-function relationships and metastasis. Thromb Haemost. 2001;86:757-71. Kontor JT. Erythropoietin for Medicine. 2001;135(6):471. Konturek JW, Bielanski W, Konturek SJ, Bogdal J, Oleksy J. Distribution and release of epidermal growth factor in man. Gut. 1989:30;1194-1200. Kooistra M, van Es A, Marx J, Hertsig M, Struyvenberg A. Low-dose aspirin does not prevent thrombovascular accidents in low-risk haemodialysis patients during treatment with recombinant human erythropoietin. Nephrol Dial Transplant. 1994;9:1115-20. Korc M, Chandrasekar Beger HG. Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor alpha. J. Clin. Invest. 1992;90:1352-60. of alfa administered once every 3 (Q3W) or 4 (Q4W) weeks in patients with solid tumors. Proc Am Soc Clin Oncol. 2002;21:1421. Kotasek Poulsen E, Colowick A, Rossi G, Mackey J for the Aranesp 980291 Study Group. Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumors receiving chemotherapy: Results of a double-blind, placebo-controlled, randomized study. Eur J Cancer. 2003;39:2026-34. Kotasek D, Canon, J, Mateos M, Hedenus M, Rossi G, Taylor K. A randomized controlled trial comparing darbepoetin Alfa/correction maintenance dosing with weekly dosing for treating 2007; AA, randomized comparison of alfa with epoetin for chemotherapy induced anemia in nonhematological tumors. Journal of Clinical Oncology. 2006. 24(18S):18554. Kotsori A, Alexopoulos C. A randomized comparison of darbepoetin alfa with epoetin for chemotherapy induced anemia in nonhematological tumors. Journal of Clinical Oncology. 2006:24(20 Koury M, Semenza G. Localization of cells producing erythropoietin in murine liver by in situ hybridization. Blood. 1991;77:2497-2503. Krzyzanski W, Jusko W, Wacholtz M, Minton N, Cheung W. Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after multiple subcutaneous doses in healthy subjects. Eur J Pharm Sci. 2005;26:295-306. Kumar S, Yu H, Fong D. Erythropoietin activates the phosphoinositide 3-kinase/Akt pathway in human melanoma cells. Melanoma Res. 2006;16:275-83. Kunikane H, Watanabe K, Fukuoka M, Saijo N, Furuse K, Ikegami H, Ariyoshi Y, Kishimoto S. Double-blind randomized control trial of the effect of recombinant human erythropoietin on chemotherapy-induced anemia in patients with non-small cell lung cancer. Int J Clin Oncol. Vavra N, Sevelda P. Erythropoietin treatment under polychemotherapy O'Brien S, Estrov Z, Gutterman JU. Erythropoietin treatment in patients with myelodysplastic syndrome and anemia. Leukemia. 1991;5(11):985-90. Kurzrock R, Cortes J, Thomas DA, Jeha S, Pilat S, Talpaz M. Pilot study of low-dose interleukin-11 in patients with bone marrow failure. Journal of Clinical Oncology. 2001;19:4165-4172. Kuzel T, Esparaz B, Green D, Kies M. of intravenous 5-fluorouracil alone or in combination with cisplatin. 1990;65:885-9. EL, Jankowski J, Thayer Muir J, Fuchs CS, Kulke MH, et al. Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas. Clinical Cancer Research. 2006;12:4283-7. LaMontagne KR, Butler J, Marshall DJ, Tullai J, Gechtman Z, Hall C, Meshaw A, Farrell FX, Recombinant epoetins do not stimulate tumor growth in erythropoietin receptor-positive breast carcinoma models. Mol Cancer Ther. with sinus Neurology. 2002;58:665. Lai S, Childs E, Xi S, Coppelli F, Gooding W, Well A, Ferris R, Grandis J. Erythropoietin-mediated activation of JAK-STAT signaling contributes to cellular invasion in head and neck squamous cell carcinoma. Oncogene. 2005;24:4442-9. Lai SY, Lui VW, Koppikar Thomas BF, Intratumoral Epidermal Factor Receptor (EGFR) Antisense (AS) DNA in recurrent squamous cell carcinoma (SCCHN) of the head and neck: A phase 1 trial. Journal of Clinical Najman A. Recombinant human erythropoietin at high dose is effective for the treatment of the anemia of myelodysplastic syndromes. Contributions to Nephrology. 1991;88:271-2; discussion 273-5. Lappin receptors. Oncologist. 2003;8 (Suppl 1):15-8. Lappin T, Maxwell AP, Johnson PG. Warning flags for erythropoiesis-stimulation agents and cancer-associated anemia. The Oncologist. 2007;12:362-5. Laupacis A. Effectiveness of perioperative recombinant human erythropoietin in elective hip replacement. COPES Study Group.Lancet. 1993;342:378. Lavey R, Dempsey W. Erythropoietin increases hemoglobin in cancer patients during radiation therapy. International Journal of Radiation Oncology. 1993;27(5):1147-52. Lavey R. Clinical trial experience using erythropoietin during therapy. Strahlentherapie und Onkologie. 1998;174(Suppl IV):24-30. Lavey R, Wynnf R, Conradg M, Jiangb C, Markmanh M, Albertsi D. Recombinant human erythropoietin as an adjunct to radiation therapy and cisplatin for stage IIB-IVA carcinoma of the cervix: a Southwest Oncology Group study. Gynecologic Oncology. 2004;95:145-51. Lee A, Levine M. The thrombophilic state induced by therapeutic agents in the cancer patient. Semin Thromb Hemost. 1999;25:137-45. Lee AY, Rickles FR, Julian M, Baker RI, Bowden C, Kakkar AK, Prins M, Levine MN. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. Journal of Clinical Oncology. 2005;23(10):2123-29. Lee A. Thrombosis and cancer: the role of screening for occult cancer and recognizing the underlying biological mechanisms. Hematology Am Soc Hematol Educ Program. 2006:438-43. Leitgeb C, Pecherstorfer M, Fritz E, Ludwig H. Quality of life in chronic anemia of cancer during treatment with recombinant human erythropoietin. CANCER. 1994;73(10):2535-42. Leon P, Jim\u00e9nez M, Barona P, Sierrases\u00famaga L. Recombinant human erythropoietin for the treatment of anemia in children with solid malignant tumors. Medical and Pediatric Oncology. 1998;30:110-16. Lester J, Jo M, Campana W, Gonias S. Erythropoietin promotes MCF-7 breast cancer cell migration by an ERK/mitogen-activated protein kinase-dependent pathway and is primarily responsible for the increase in migration observed in hypoxia. J Biol Chem. 2005;280(47):39273-7. Epub 2005 Oct 5. Levin I, Cohen J, Supino-Rosin L, Yoshimura A, Watowich SS, Neumann D. Identification of a cytoplasmic motif in the erythropoietin receptor required for receptor internalization. FEBS Letters. 1998;427:164-70. Levine E, Laborde C, Hambrick E, McKnight CA, Vijayakumar S. Influence of Erythropoietin on Transfusion Requirements in Patients Receiving Preoperative Chemoradiotherapy for Rectal Cancer. Dis Colon Rectum. 1999;42(8):1065-71. Levine M, Gent M, Hirsh J, Arnold A, Goodyear M, Hyrniuk W, De Pauw S. The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N Engl J Med. 1988;318:404-7. Levine M. Cancer patients in Goldhaber SZ, Ed. Prevention of venous thromboembolism. New York: Marcel Dekker. 1993:463-83. Levine M, Hirsh Gent M, Arnold A, Warr D, Falanga A, Samosh M, Bramwell V, Pritchard K, Stewart D, Goodwin P. Double-blind randomized trial of very low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet. 1994;343:886-89. Leyland-Jones B, BEST Investigators and Study Group. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol. 2003;4:459-60. Leyland Jones B, Semiglazov Manikhas D, Baselga J, Biakhov M, Valuckas K, Voznyi E, Liu X, Vercammen E. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. 2005;23:5960-72. Epub 2005 Aug Barrett-Lee P, Branson K, Gorst D, Kaczmarski R, McAdam K, Stevenson P, Thomas R. Improvement in quality of life for cancer patients treated with epoetin alfa. European Journal of Cancer. 2001;10:183-91. Libutti MPF. Darbepoetin a, quality of life and fatigue in outpatients in chemo-radiotherapy. Journal of Clinical Oncology. 2004;22(14S):8190. Lin AY, Ryu JK, Harvey D, Sieracki B, Scudder SA, Wun T, Davis UC. Incidence of symptomatic venous thrombosis in cervical and vulvo-vaginal carcinoma treated with concurrent chemoradiation, erythropoietin, and coumadin. Journal of Clinical Oncology. 2004;22(14S):8101. Lin A, Ryu J, D, Sieracki B, Scudder S, Wun T. Low-dose warfarin does not decrease the rate of thrombosis in patients with cervix and vulvo-vaginal cancer treated with chemotherapy, radiation, and erythropoietin. Gynecologic Oncology. 2006;102:98-102. Lin F, Suggs S, Lin C, Browne JK, Smalling R, et al. Cloning and expression of the human erythropoietin gene. Proc. Natl. Sci. A, Fouladiun M, Lundholm K. Effects of recombinant erythropoietin in palliative treatment of unselected cancer patients. Clinical Cancer Research. 2004;10:6855-64. Link H, Arseniev L, B\u00e4hre, Kada JG, Diedrich H, allogeneic blood cells. Blood. 1996;87:4903-9. Linnekin D, Evans G, D'Andrea D, Farrar W. Association of the erythropoietin receptor with protein tyrosine kinase activity. Proc Natl Acad Sci Lipton A, Harvey H, Hamilton R. Venous thrombosis as a side effect of tamoxifen treatment. Cancer Treat Rep. 1984;68:887-9. List A. Vascular Endothelial Growth factor Signaling Pathway as an Emerging Target in Hematologic Malignancies. The Oncologist. 2001;6:24-31. List AF. New of myelodysplasia. The Oncologist. 2002;7(suppl 1):39-49. List A, Kurtin Mahadevan D, Fuchs D, Rimsza L, Heaton JB. Efficacy of lenalidomide in myelodysplastic syndromes. The New England Journal of Medicine. 2005;352:549-57. Littlewood TJ. Erythropoietin for the treatment of anemia associated with hematological malignancy. Hematology & Oncology. 2001;19:19-30. Littlewood J, Vercammen E, Rapoport B, Epoetin Alpha Study Group. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of Miguel J, Hendricks L, Hedenus M. Efficacy of darbepoetin alfa in alleviating fatigue and the effect of fatigue on quality of life in anemic patients with lymphoproliferative malignancies. Journal of Pain and Symptom Management. 2006;31(4):317-325. Stura EA, Middleton SA, IA. evidence for preformed dimers of erythropoietin receptor before ligand activation. Science. 1999;283(12):987-91. Lockich J, Becker B. Subclavian vein thrombosis in patients treated with infusion chemotherapy for advanced malignancy. Cancer. 1983;52:1586-9. Lokich JJ, Becker B. Subclavian vein thrombosis in patients treated with infusion chemotherapy for advanced malignancy. Cancer. 1983;52:1586-9. Luban NL. Transfusion Safety: Where are we today? Annals New York Academy of Sciences. 2005;1054:325-41. Ludwig H, Fritz E, Kotzmann H, Hocker P, Gisslinger H, Barnas U. Erythropoietin Treatment of Anemia Associated With Multiple Myeloma. The New England Journal of Medicine. 1990;322(24):1693-99. Ludwig H, Fritz E, Kotzmann H, Gisslinger H. Erythropoietin treatment of tumor-associated anemia. Onkologie. Ludwig Fritz E, Kotzmann H, Hocker P, Gisslinger H, Barnas U. Treatment of anemia associated with multiple myeloma[Letter to the editor]. The New England Journal of Medicine. 1991;324(1):62-3. Ludwig H, Leitgeb C, Fritz E, Krainer M, Kuhrer I, Kornek G, Sagaster P, Weibmann A. Erythropoietin treatment of chronic anaemia of cancer. European Journal of Cancer. 1993;29A(Suppl 2):S8-S12. Ludwig H, Fritz E, Leitgeb C, Krainer M, Kuhrer I, Sagaster P, Umek H. Erythropoietin treatment for chronic anemia of selected hematological malignancies and solid tumors. Annals Oncology. 1993;4:161-7. Ludwig H, Pecherstorfer M, Leitgeb C, Fritz E. Recombinant human erythropoietin for the treatment of chronic anemia in multiple myeloma and squamous cell carcinoma. Stem Cells. 1993;11:348-55. Ludwig H, Fritz E, Leitgeb C, Pecherstorfer M, Samonigg H, Schuster J. Prediction of response to erythropoietin treatment in chronic anemia of cancer. Blood. 1994;84(4):1056-63. Ludwig H, Chott A, Fritz E, Krainer M. Increase of bone marrow cellularity during erythropoietin treatment in myeloma. Stem Cells. Beinhauer A, Samonigg H, Kappeler AW, Fritz E. Recombinant Human Erythropoietin for the Correction of Cancer Associated Anemia with and without Concomitant Cytotoxic Chemotherapy. Cancer. 1995;76(11):2319-2329. Ludwig H. rHuEPO and preclinical experience. Oncologist. 2004;9(suppl 5):48-54. Ludwig H, Van Belle S, Barrett-Lee P. The European cancer anaemia survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence and treatment of anaemia in cancer patients. Eur J Cancer. 2004;40:2293-2306. Ma X, Does M, Raza A, Mayne S. Myleodysplastic Syndromes Incident and United States. Wiley Intersciecne. 2007: 10: 1536-1542. Macdougall I, Davies M, Hallett I, Cohlin D, Hutton R, Coles G, Williams J. Coagulation in studies and fistula blood flow during erythropoietin therapy in haemodialysis patients. Nephrol Dial Transplant. 1991;6:862-7. Macdougall I, Roberts DE, Coles GA, Williams JD. Clinical pharmacokinetics of epoetin (recombinant human erythropoietin). Clin Pharmacokinet. 1991;20(2):99-113.- Macdougall IC. Poor response to erythropoietin. British Medical Journal. 1995;310:1424-5. MacDougall I, Gray S, Elston O, Breen C, Jenkins B, Browne J, Egrie J. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol. 1999;10:2392-5. MacDougall I. Optimizing the use of erythropoietic agents\u2014pharmacokinetic and pharmacodynamic considerations. Nephrol Dial Tare N. CERA (Continuous Erythropoiesis Receptor Activator) for the treatment of renal anemia: an innovative agent with unique receptor binding characteristics and prolonged serum half-life. J Am Soc Nephrol. 2003;14:769A. MacDougall I. CERA (Continuous Erythropoietin Receptor Activator): a new erythropoiesis-stimulating agent for the treatment of anemia. Curr Hematol Rep. 2005;4:436-40. MacLennan S, Williamson LM. Risks of fresh frozen plasma and platelets. The Journal of Trauma Injury, Infection, and Critical Care. 2006;50(6):S46-50. Machtay M, Pajak T, Definitive radiotherapy +/- erythropoietin for squamous cell carcinoma of the head and neck: Preliminary report of RTOG 99-03. Y, Miyatake J, Matsuda M, Hasegawa H, Kanamaru A. Possible involvement of soluble erythropoietin receptor in resistance to erythropoietin in patients with renal anemia. Am J Nephrol. 2001;21:426. Maisnar V, Chroust K. Treatment of associated anemia in different hematological disorders with epoetin alpha. Neoplasma. 2004;51:375-84. Malik I, Khan Z, Hakimali A, Sabih M, Rehman G. The effect of subcutaneous recombinant human erythropoietin (r-HuEPO) on anemia in cancer patients receiving platinum-based chemotherapy. Journal of the Pakistan Medical Association. 1998;48(5):127-31. Malik I, Kahanic S, Liu R, Tchekmedyian S, Tomita D, Lillie T, Boccia R. Effectiveness of darbepoetin alfa administered every 3 weeks on clinical outcomes in patients with gastrointestinal cancer and chemotherapy-induced anemia. 2006 Gastrointestinal Cancers Symposium. Abstract #382. Malmstrom H, Karlsson T. Cognitive functions in patients with ovarian cancer receiving chemotherapy. Proc Am Soc Clin. 2003;22:1855. A-Malyszko A, Mysliwiec C, Buczko W. A study of platelet functions, some hemostatic and fibrinolytic parameters in relation to serotonin in hemodialyzed patients under erythropoietin therapy. Thromb Res. 1995;77:133-43. B-Malyszko J, Maschio G. Erythropoietin 2):74-9. Malyszko uremic platelet aggregation in vivo and in vitro. Int L, Gardin C, Quarre MC, Bernard JF, Giraudier S, et al. High response rate to darbepoetin alfa in \"low risk\" results of a phase II study. Blood. 2004;104:abstract Mannone L, Gardin C, Quarre Hamza Beyne-rauzy MO, Cheze S, Giraudier S, Agape P, L, Voillat L, Dreyfus F, Fenaux P. High-dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II study. British Journal of Haematology. 2006;133:513-19. Mantovani L, Lentini H. Treatment of anaemia in myelodysplastic syndromes with prolonged administration of recombinant human granulocyte colony-stimulating factor and erythropoietin. British Journal of Haematology. Mele E, Giotta F, Cantinieri Pretreatment normalization of mild anemia with epoetin alfa: impact on the outcome in epithelial ovarian cancer patients. Proc Am Soc Clin Oncol. Latiano T. Pretreatment normalization of mild anemia with epoetin alfa predicts long-term outcome for women with epithelial ovarian cancer. Journal of Clinical Oncology. 2004;22(14S):5132. Markman M, Reichman B, Hakes T, Rubin S, Jones W, Lewis J Jr, Barakat R, Curtin J, Almadrones L, Hoskins W. The use of recombinant human erythropoietin to prevent carboplatin-induced anemia. Gynecologic Oncology. 1993;49:172-76. Markman M. The prophylactic administration of recombinant erythropoietin in the management of ovarian cancer: time for a definitive Phase 3 randomized trial. Gynecologic Oncology. 2002;86:237-8. Markman M. Use of progression-free survival as a valid endpoint in phase II cancer clinical trials. Current Oncology Reports. 2007;9:159-60. Marques da Costa R. Current use of recombinant human erythropoietin (r-huEPO) in the management of symptomatic anaemia Increased blood cell destruction during vigorous regeneration of bone marrow after intensive chemotherapy for non-hodgkin lymphoma. European Journal of Haematology. 1993;29A(10):1499. Maschio G. hypertension. Nephrol Dial Transplant. 1995;10(Suppl 2):74-9. Masinar V, Khroust K. Treatment of associated anemia different hematological disorders with epoetin alfa. Neoplasma. Y, Gallyas F Jr, Tabira T, Sasaki R. Functional erythropoietin receptor of the cells with neural characteristics. Comparison with receptor properties of erythroid cells. J Biol Chem. 1993;268:11208-16. Matsuda A, Kishimoto K, Yoshida K, Yagasaki F, Ito Y, Sakata T, Kawai N, Ino H, Hirashima K, Bessho M. Long-term follow-up of patients with aplastic anemia and refractory anemia responding to combination therapy with recombinant human granulocyte colony-stimulating factor and erythropoietin. International Journal of Hematology. 2002;76:244-50. Matsuda K, Idezawa T, You XJ, Kothari H, Korc M. Multiple mitogenic pathways in pancreatic cancer cells are blocked by a truncated epidermal growth factor receptor. Cancer Research. 2002;62:5611-7. Maurer A, Seipelt G, Ottmann OG, Geissler GR, Hoelzer D. Changes in erythroid progenitor cell and accessory cell compartments in patients with myelodysplastic syndromes during treatment with all-trans retinoic acid and haemopoietic growth factors. British Journal of Haematology. 1995;89(3):449-51.. McKenzie RS. Use of erythropoietic agents in anemic lung cancer patients receiving chemotherapy. Proc Am Soc Clin Oncol. 2003;22:3145. McMahon F, Vargas R, Ryan M, Jain A, Abels R, Perry B, Smith I. Pharmacokinetics and effects of recombinant human erythropoietin after intravenous and subcutaneous injections in healthy volunteers. Blood. 1990;76:1718-22. Medical News Today. EGFr targeted drugs: vectibix setback, EGFr testing. April 4, 2007. Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. Journal of Clinical Oncology. 2003;21(14):2787-99. Mercadante S, cancer: pathophysiology and treatment. Cancer Treat Rev. 2000;26:303-11. Michael U, Jackisch C, Lenhard MS, DuBois A, Lueck Thomssen R, Mob\u00fcs, VJ. Epoetin-alpha reduces red blood cell transfusions (RBC) in high-risk breast cancer patients with adjuvant dose-dense, sequential chemotherapy with epirubicin (E) paclitaxel (T) and cyclophosphamide (C) (ETC). Journal of Clinical Oncology. 2005;23(16S):613. Migliorino MR, De Petris L, Martelli O, Mancuso A, DiSalvia R, Demarinis F. Hemoglobin increase in advanced/metastatic lung cancer patients receiving multicycle chemotherapy and weekly darbepoetin alfa: an initial ongoing experience. Journal of Clinical Oncology. 2004;22(14S):8250. Mikami Y, Mikami M, Nannmoku H, Kawashima H, Sasaki T, Hada R, Inoue S. Anemia-inducing factor expressed in gastric cancer is homologous with complement regulatory factor CD59? J Exp Clin Cancer Res. 1998;17:355-60. Miller AM, Noyes WE, Taetle R, List AF. Limited erythropoietic response to combined treatment with recombinant human interleukin 3 and erythropoietin in myelodysplastic syndrome. Leukemia Research. 1999;23:77-83. Miller B, Jones J, Piantadosi S, Abeloff M, Spivak J. Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med. 1990;322:1689-92. Miller CP, mediates erythroid and J, Hankins WD, Sugamura K, erythropoietin responsiveness of T lymphocytes retrovirally transduced with Gottardello F, Bordon P, Montini G, Forestqa C. Evidence for specific binding and stimulatory effects of recombinant human erythropoietin on isolated adult rat Leydig cells. Acta G, Tomita D, McGuire W. III. Every-2-week darbepoetin alfa is comparable to rHuEPO in NT, Tchekmedyian NS, et al. Darbepoetin alfa administered every two weeks (Q2W) reduces chemotherapy-induced anemia (CIA) to the same extent as recombinant human erythropoietin (rHuEPO) but with less-frequent D, Peled A. Erythropoietin induces tumor regression and anti tumor immune responses in murine myeloma models. Z, Magazanik A, Lewinski UH, Cohen A. Recombinant human erythropoietin in the treatment of multiple myeloma-associated anemia. Acta Haematologica. 1997;98:204-10. Mittelman M, Zeidman Katz O, Oster H, Rund D, Neumann D. Erythropoietin has an anti-myeloma effect-a hypothesis based on a clinical observation supported by animal studies. European Journal of Haematology. 2004;72:155-65. Moebus V, Bastert M, Jackish C, Kliniken S. Epoetin alpha prevents anemia and transfusions of Rbcs in patients (pts) receiving dose-dense sequential with epirubicin (E), paclitaxel (T) and cyclophosphamide (C) (ETC) is superior to conventional dosed chemotherapy in high-risk breast cancer patients (=4+LN). First results of an AGO-trial. Journal of Clinical Oncology. RG, O'Connell MJ, al. Therapy of locally unrespectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads+5-fluorouracil), and high-dose radiation + 5-fluorouracil: the gastrointestinal tumor study group. Cancer. 1981;48(8):1705-10. Mohr B, Herrmann, Huhn D. Recombinant human erythropoietin myelodysplastic syndrome and myelofibrosis. Acta Haematol. 1993;90:65-70. Mohyeldin A, Lu H, Dalgard C. Erythropoietin signaling promotes invasiveness of human head and neck squamous cell carcinoma. Neoplasia 2005;7:536-43. Molica S. Erythropoietin Treatment of Anaemia Associated with Lymphoproliferative Disorders. Eur J Cancer. 1993;29A(Letters):1499-50. Monreal M, Lafoz E, J, Valls Upper-extremity deep venous thrombosis and pulmonary embolism. A prospective study. Chest. 1991;99:280-3. Moritz K, Lim G, Wintour E. Developmental regulation of erythropoietin and erythropoiesis. Am. J. Physiol. 1997;273:R1829-44. Mortimer J, Bardwell W, Blair S, Podbelewicz-Schuller Y. Correlation between hemoglobin and quality of life in women undergoing adjuvant chemotherapy for breast cancer. Journal of Clinical Oncology. 2005;23(16S):590. Moullet I, Salles Niedhardt-Berard E, Thieblemont C, Feldman P, Coiffier B. Frequency and significance of anemia in non-Hodgkin's lymphoma patients. Ann Oncol. 1998;9:1109-15. Mundle Bourezak A, V. Erythroid response (ER) rates in myelodysplastic syndromes (MDS) patients treated with epoetin alfa (EPO) or darbepoetin alfa (DARB) using international working group response criteria (IWGc): comparative meta-analysis. Blood. 2006;108(11):abstract#2672. Munker R, Hasenclever D, Brosteanu Diehl V. Bone marrow involvement in Hodgkin's disease: an analysis of 135 consecutive cases. German Hodgkin's Lymphoma Study Group. J Clin Oncol. 1995;13:403-9. Mu\u00f1oz-Langa Olmos are similar to three-times-weekly dosing to improve hemoglobin levels in chemotherapy patients: results from multicenter prospective cohort study. Journal of Clinical Oncology. 2005;23(16S):8161. Murphy L, Cluck MW, Lovas Schally J, Larsson J, Knezetic JA, Adrian TE. Pancreatic cancer cells require an EGF receptor-mediated autocrine pathway for proliferation in serum-free conditions. British Journal of Cancer. 2001;84(7):926-35. Murphy M, Wallington T, Kelsey P, Boulton F, Bruce M, Cohen H, Duguid J, Knowles S, Poole G, Williamson L, British Committee for Standards in Hematology. Guidelines for the clinical use of red cell transfusions. British Journal of Haematology. 2001;113:24-31. Musto P, Falcone A, Carotenuto M. Granulocyte and Erythropoietin for the Anemia of Myelodysplastic Syndromes: A Real Improvement With Respect to Erythropoietin Alone? 1994;84(5):1687-8. Musto P, Falcone A, Carotenuto M. Low serum levels of tumor necrosis factor and interleukin-1 \u00df in myelodysplastic syndromes responsive Alicino A, G, Scalzulli P, Perla G, Carotenuto M. Modifications of Erythropoiesis in Myelodysplastic Syndromes Treated With Recombinant Erythropoietin As Evaluated By Soluble MM, Lombardi GF, Modoni S, Longo A, Carotenuto M. Clinical results of recombinant erythropoietin in transfusion-dependent patients with refractory multiple myeloma: role of cytokines and monitoring of erythropoiesis. Journal Haematology. A, Bodenizza C, Perla G, and Carotenuto M. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with meylodysplastic syndromes unresponsive to erythropoietin A, Perla G, Carella AM. Efficacy of a single, weekly dose of recombinant erythropoietin in myelodysplastic syndromes. British Journal of Haematology. G, C, PR, Sala Campioni D, Ghio R, Cascavilla N, Carella AM. Darbepoetin alpha the treatment of anaemia in risk syndromes. Falcone Sanpaolo G, Bodenizza C. Combination of erythropoietin and thalidomide for the treatment of anemia in patients with myelodysplastic syndromes. Leukemia Research. 2006;30:385-8. Mystakidou ML, Vlahos L. Evaluation of epoetin supplemented with oral iron in patients with solid malignancies and chronic anemia not receiving anticancer treatment. Anticancer Research. 2005;25:3495-3500. Nakamura Y, Komatsu N, Nakauchi H. A truncated erythropoietin receptor that fails to prevent programmed cell death of erythroid cells. Science. 1992;257:1138-41. Nakamura N, Chin H, Miyasaka N, Muira O. An Transduces a growth Signal in Hematopoietic Cells. The Journal of Biological Chemistry. 2001;271:19483-19488. Narhi L, Arakawa T, Aoki K, Elmore R, Rohde M, Boone T, Strickland T. The effect of carbohydrate on the structure and stability of erythropoietin. J Biol Chem. 1991;266:23022-6. Narhi L, Aoki K, Philo J, Arakawa T. Changes in conformation and stability upon formation of complexes of erythropoietin (EPO) and soluble EPO receptor. J Protein Chem. 1997;16:213-25. Narhi L, Arakawa T, Aoki K, Wen J, Elliot S, Boone T, Cheetham J. Asn to Lys mutations at three sites which are N-glycosylated in the mammalian protein that decrease the aggregation of Escherichia coli-derived erythropoietin. Protein Eng. 2001;14:135-40. National Cancer Institute. http://ctep.cancer.gov/forms/ctcaed3.pdf 5]; accessed 4/9/07. National Comprehensive Cancer Network www.nccn.org. www.nccn.org/professionals/physicians_gls/PDF/anemia.pdf. Accessed 4/5/07 A - National Institute for Health and Clinical Excellence (NICE). Final appraisal determination: Erythropoietin for anaemia induced by cancer treatment. 2006;March:1-23. www.guidance.nice.org.uk. Accessed 3/18/07. B - National Institute for Health and Clinical Excellence (NICE). Appraisal of erythropoietin for anaemia induced by cancer treatment. Decision of the panel. 2006;September:1-31. www.guidance.nice.org.uk. Accessed 3/18/07. Natori stimulates Stein R, Vardiman J, Doherty K, Cornwell J, Krantz S, Greenberg P. Treatment of the anemia of myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor in combination with erythropoietin. Blood. 1993;82(3):737-43. Negrin R, Stein R, Doherty K, Cornwell J, Vardiman J, Krantz S, Greenberg P. Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: for in vivo synergy. Blood. 1996;87(10):4076-81. Nestel P, Davidsson L. Anemia, iron deficiency, and iron deficiency anemia. Reviewed by INACG Steering Committee. 2002. Neumeister P, Jaeger G, Eibl M, Sormann S, Zinke W, Linkesch W. in Combination with erythropoietin and G-CSF promotes multilineage hematopoiesis in patients with myelodysplastic syndrome. Leukemia and Lymphoma. 2001;40:345-9. New York Times - Business Section. Sec asks Amgen about anemia drugs. 3/1/07. Accessed Tynell E, \u00c5kerblom O. Cumulative risks of early fresh frozen plasma, cryoprecipitate and platelet transfusion in Europe. The Journal of Trauma Injury, Infection, and Critical Care. 2006;60(6):S41-45. Nordyke RJ, Chang C, Chiou C, Wallace JF, Yao B, Schwartzberg LS. Validation of a patient satisfaction questionnaire for anemia treatment, the PSQ-An. Health and Quality of Life Outcomes. 2006;4:28. Notification to all users of practice guidelines (special announcement). Arch Pathol Lab Med. 2002;126:401. Oberhoff C, Neri B, Amadori R, Netter-Pinon J, Tubiana-Mathieu N, Zwierzina H. Recombinant human erythropoietin in the treatment of chemotherapy-induced anemia and prevention of transfusion requirement associated with solid tumors: a randomized, controlled study. Annals of Oncology. 1998;9:255-60. Oberhoff C. Speed of haemoglobin response in patients with cancer: a review of the erythropoietic proteins. Support Care Cancer. 2006;15(6):603-11. Obralic N, Bilenjki D, Bilbija Z. Prognostic importance of anemia related parameters in patients with carcinoma of the cervix uteri. Acta Oncol. 1990;29:199-201. Oda K, Matsuoka Y, Funahashi A, Hiroaki K. A comprehensive pathway map of epidermal growth factor receptor signaling. MSB journal.2007; 1:1-2. Oehler W, Fisher J, Merkle K. Does the initial hemoglobin value modify the primary tumor reaction? A study of 264 irradiated brochial cancers. Radiobiol 1990;31:325-31. Ogilvie Liu C, Ruegg U, Noguchi C. Erythropoietin stimulates proliferation and interferes with differentiation of myoblasts. J Biol Chem. 2000;275:39754-61. Ohashi H, Maruyama K, Liu Y, Yoshimura A. Ligand-induced activation of chimeric receptors between the erythropoietin Horton J , Davis T, McFadden E, Carbone P. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-55. Okuno Y, Takahashi T, Suzuki A, Ichiba S, Nakamura K, Hitomi K, Sasaki R, Imuro H. Expression of the erythropoietin receptor on a human myeloma cell line. Biochemical and Biophysical Research Communications. P. Combined administration of alpha-erythropoietin and filgrastim can improve the outcome and cost balance of autologous stem cell transplantation in patients with lymphoproliferative disorders. Bone Marrow Transplantation. 2004;34:693-702. Olsson A, Svensson J, Sundstr\u00f6m J, Bergstr\u00f6m S, Edekling T, Carlsson G, Hansen J, Svensson B, Albertsson M. Erythropoietin treatment in metastatic breast cancer: Effects on hb, quality of life and need for transfusion. Acta Oncologica. 2002;41:517-24. Olujohungbe A, Handa S, Holmes J. Does erythropoietin accelerate malignant transformation in multiple myeloma? Postgrad Med J. 1997;73:163-4. O'Shaughnessy J. Effects of epoetin alfa on cognitive function, mood, asthenia, and quality of life in women with breast cancer undergoing adjuvant chemotherapy. Clinical Breast Cancer. 2002;3(Suppl 3):S116-20. O'Shaughnessy J, Vukelja S, Holmes F, Savin M, Jones M, Royall D, Geroge M, Von Hoff D. Feasibility of quantifying the effects of epoetin alfa therapy on cognitive function in women with breast cancer undergoing adjuvant or neoadjuvant chemotherapy. Clinical Breast Cancer. 2005;5:439-46. Oster HS, Hoffman M, Prutchi-Sagiv S, Katz O, Neumann D, Mittelman M. Erythropoietin in clinical practice: current use, effect on survival, and future directions. Isr Med Assoc J. 2006;8(10):703-6. Ord\u00f3\u00f1ez A, Gonz\u00e1lez-Bar\u00f3n Sanchez A, Arrivi A, Manzano J. Epoetin beta treatment to prevent anemia in solid tumor patients receiving platinum-based chemotherapy. Journal of Clinical Oncology. 2005;23(16S):8230. \u00d6sterborg G, J\u00e4ger G, Najman A, Peest D for the European Study Group of Erythropoietin (Epoetin Beta) Treatment in Multiple Myeloma and Non-Hodgkin's Lymphoma. Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-hodgkin's lymphoma Iosava G, Abdulkadyrov Hedenus M, Messinger D the Epoetin Beta Hematology Study Group. Randomized, double-blind, placebo-controlled trial of epoetin-\u00df on survival of patients with lymphoproliferative malignancies: long-term follow up of a large randomized study. British Journal of Haematology. 2005;129:206-9. \u00d6sterborg AC, De Boer R, Clemens M, Renczes Kotasek D, Prausova J, Marschner N, Hedenus agent (AMG114) with 131-hour half-life effectively treats chemotherapy-induced anemia when administered as 200 mcg every 3 weeks. Journal of Clinical Oncology. 2006;24(18S):8626. \u00d6sterborg A, Steegmann J, Hellmann A, Couban S, Mayer J, Eid J. Phase II study of three dose levels of continuous erythropoietin receptor activator (C.E.R.A.) in anaemic patients with aggressive non-Hodgkin's lymphoma receiving chemotherapy. British Journal of Haematology. 2007;136:736-44. Aapro M, Cornes P, Haselbeck A, Hayward CRW, Jelkmann W. Preclinical studies of erythropoietin receptor expression in tumour cells: impact on clinical use of erythropoietic proteins to correct cancer-related anaemia. European Journal of Cancer. 2007;43:510-9. Pajonk F, Weil A, Sommer A, Suwinski R, Henke M. The erythropoietin-receptor pathway modulates survival of cancer cells. Oncogene. 2004;23:8987-91. Panares R, Garcia A. Bevacizumab in the management of solid tumors. Expert Rev Anticancer Ther. 2007;7:433-45. Pancreatic Cancer Research. Newsletter. \"Pancreatic cancer, pancreas and cancer treatment. Accessed 2/21/07. Papaldo P, Ferretti G, Di Cosimo S, Giannarelli Lopez Cortesi M, Terzoli E, Carlini P, Vici P, C, Di Lauro L, Naso G, Nistico C, Mottolese M, Di Filippo F, Ceribelli A, and Cognetti F. Does Granuloctye Colony-Stimulating Factor Worsen Anemia in early Breast Cancer Patients Treated With Epirubicin any Cyclophosphamide? Journal of Clinical Oncology. 2006;24:3048-55. Papatheofanis Suruki Y, Scheye R, Drielick M, Nalysnyk L. A pooled analysis of observational data evaluating usage and clinical outcomes of erythropoietic agents. Journal of Clinical Oncology. 2004;22(14S):6144. Pappalardo A, Giuffrida D, Castorina S, Russo R, Rosario C, Marino O, Failla G. Epoetin alfa (100,000 U in 8 consecutive days) in treatment of anemic \"home care\" patients with advanced cancer. Proc Am Soc Paquette R, Gabrilove Sekeres M, Lam H, Dreiling L. Darbepoetin alfa for treating anemia in low-risk myelodysplastic syndrome patients: interim results after 27/28 weeks. American of Clinical Oncology. 2006;24(18S):6564. Pasqualetti P, Collacciani A, serum erythropoietin in myelodysplastic syndromes. European Review for Medical and Pharmacological Sciences. 2000;4:111-5. Patrick D, Abels R, Larholt K, Krantz. Recombinant human erythropoietin (rHuEPO) for the treatment of the anemia of cancer. The Oncologist. 1996;1:140-50. Patrick DL, Gagnon MJ, Mathijs R, Sweetenham J. European Journal of Cancer. 2003; 39:335-345. Assessing the clinical significance of health-related quality of Life (HrQOL) improvements in anaemic cancer patients receiving epoetin alfa. 2003; 39;335-345. Patton J, Camp M, Kuzur M, Liggett W, Miranda F, Varsos H, Porter L. Epoetin alfa (Procrit) 60,000 U once-weekly followed by 120,000 U every three weeks to maintain hemoglobin levels in anemic cancer patients receiving chemotherapy. Proc Am Soc Clin Oncol. 2002;21:1469. Patton J, Kuzur W, Miranda F, Varsos H, Porter L. Epoetin alfa 60,000 u once weekly followed by 120,000 u every three weeks maintains hemoglobin levels in anemic cancer patients receiving chemotherapy: final report. Proc Am Soc Clin Oncol. 2003;22:3033. Patton JF, Sullivan T, Mun Y, Reeves T, Rossi G, Wallace JF. A retrospective cohort study to assess the impact of therapeutic substitution of darbepoetin alfa for epoetin alfa in anemic patients with myelodysplastic syndrome. Support Oncology. Perillo A, Pierelli Salerno M, Bonanno G, Fattorossi A, Leone G, Mancuso S, Menichella G. Peripheral blood progenitor cell collection after epirubicin, paclitaxel, cisplatin combination Mancuso S, Scambia G. Cytokines alone for PBPC collection in patients with advanced gynecological malignancies: G-CSF vs G-CSF plus EPO. Bone Marrow Transplantation. 2004;34:743-44. Peterson M, Mao Q, Schwartzberg LS, Fortner BV. Higher rates of early response needed with epoetin alpha (epo) and darbepoetin alpha in the community Filice L, Valentini Villa RS, Mandelli F. Treatment of Myelodysplastic Syndromes (MDS) With Recombinant Human Erythropoietin (rHuEPO): Preliminary Clinical Results reported at the Second International Conference on Myelodysplastic Syndromes. April 90 to March 91, Page 33. Phillips T, Li Y, Kim K, McBride WH, Pajonk F. Erythropoietin affects the number of CD24-/low/CD44+ breast cancer initiating cells. American Association for Cancer Research. 2007;Los Angeles: April14-18. Pierelli L. Perillo Menichella G, Fattorossi A, Leone G, Mancuso S, addition factor cisplatin combination chemotherapy: a of Oncology. Pierelli G, Rumi C, Zini G, d'Onofrio G, Leone G, Mancuso S, Bizzi B. In vitro and in vivo effects of recombinant human erythropoietin plus recombinant human G-CSF on human haemopoietic progenitor cells. Bone Marrow Transplantation. 1994;14:23-30. Pineo G, Regoeczi E, Hatton M, Brian M. The activation of coagulation by extracts of mucus: a possible pathway of intravascular coagulation accompanying adenocarcinomas. Toniutto P, Bartoli E. Thrombocytopenia of chronic liver disease corrected by erythropoietin treatment. J Hepatol. 1994;21:376-80. Pirker R, Vansteenkiste J, Gately J, Yates Musil J. A Phase 3, Double-blind, placebo-controlled, randomized study of novel erythropoiesis stimulating protein (NESP) in patients undergoing platinum treatment for lung cancer. Proc Am Soc Clin Oncol. 2001;20:1572. Platanias L, Miller C, Mick R, Hart R, Ozer H, McEvilly J, Jones R, Ratain M. Treatment of chemotherapy-induced anemia with recombinant human erythropoietin in cancer patients. J Clin Oncol. 1991;9:2021-26. Porter J, Leahey A, Polise K, Bunin G, Manno, C. Recombinant human erythropoietin reduces the need for erythrocyte and platelet transfusions in pediatric patients with sarcoma: a randomized, double-blind, placebo-controlled trial. Journal of Pediatrics. Lancet Oncol. 2005;6:401-10. Pritchard K, Paterson A, Paul N, Zee B, Fine S, Pater J. Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group. J Clin Oncol. 1996;14:2731-7. Pruneri G, 1398-1401. Prunier F, Pfister O, Hadri L, Liang L, del Monte F, Liao R, Hajjar RJ. Delayed erythropoietin therapy reduces post-MI cardiac remodeling only at a dose that mobilizes endothelial progenitor cells. Am J Physiol Heart Cir Physiol. 2007;292:H522-9. The Pure Red Cell Aplasia Global Scientific Advisory Board (GSAB). Erythropoietin-induced, antibody-mediated pure Quirt I, Micucci S, Moran L, Pater J, Browman G. The role of recombinant human erythropoietin (EPO) in reducing blood transfusions and maintaining the quality of life (QOL) in patients with lymphoma and solid tumors requiring cytotoxic chemotherapy. Results of a double-blind, Robeson C, Lau C. Epoetin alfa therapy increases hemoglobin levels and improves quality of life in patients with cancer-related anemia who are not receiving chemotherapy and patients with anemia who are receiving chemotherapy. J Clin Oncol. 2001;19:4126-34. Quirt I, Kovacs M, Couture F, Turner A, Noble M, Burkes R, Dolan S, Plante R, Lau C, Chang J, Camacho F. Patients previously transfused or treated with epoetin alfa at low baseline hemoglobin are at higher risk for subsequent transfusion: an integrated analysis of the Canadian experience. The Oncologist. 2006;11:73-82. Rafanelli D, Grossi A, Longo G, Vannucchi AM, Bacci P, Ferrini PR. Recombinant human erythropoietin for treatment of myelodysplastic syndromes. Leukemia. 1992;6:323-7. Ramakrishnan R, Cheung N, Jusko W. Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after single and multiple doses in healthy volunteers. J Clin Pharmacol. 2004;44:991-1002. Rankin E, Biju M, Liu Q, Unger T, Rha J, Johnson R, Simon M, Keith B, Haase V. Hypoxia-inducible factor-2 (HIF-2) in multiple myeloma[Letter to the editor]. New England Journal of Medicine. 2006;354(19):2079-80. Razzano M, Caslini C, Cortelazzo S, Battistel V, Rambaldi A, Barbui T. Therapy With Human Recombinant Erythropoietin in Patients With Myelodysplastic Syndromes. British Journal of Haematology. S, Battistel V, Rambaldi A, and Barbui T. Clinical and Biological Effects of Erythropoietin treatment of Myelodysplastic Syndrome. Leukemia and Lymphoma. 1993;10:127-34. study once-weekly epoetin alfa in children with cancer undergoing myelosuppressive chemotherapy. Journal of Clinical Oncology. 2004;22(14S):8527. Razzouk B, Hord Hockenberry Williams D, Rackoff W. Double-blind, placebo-controlled study of quality of life, hematologic end points, and safety of weekly epoetin alfa in children with cancer receiving myelosuppressive of a randomized study of every three-week dosing (Q3W) of chemotherapy-induced anemia (CIA). Journal of Clinical Oncology. 2004;22(14S):8064. Reed W, Hussey D, DeGowin R. Implications of anemia of chronic disorders in patients anticipating radiotherapy. Am J Med Sci. 1994;308:9-15. Erratum in Am J Med Sci. 1994;308:288. Reed N, Chan S, Hayward C, Burger H, Huinink WTB. Impact of epoetin beta on the survival of anemic patients with ovarian cancer receiving platinum-based chemotherapy. Journal of Clinical Oncology. 2005;23(16S):5102. Reinhardt U, Tulusan A, Angermund R, Lutz H. Increased Hemoglobin Levels and Improved Quality-of-Life Assessments During Epoetin Alfa treatment in Anemic Cancer Patients :Results of a prospective, Multicenter German Trial. The D, Quarenta M, Colucci G, Schittulli F. A prothrombotic state in breast cancer patients treated with adjuvant chemotherapy. Breast Cancer Res Treat. 1996;40:151-9. Remacha AF, Arrizabalaga M, FA, Malcorra JJ, Equiza EP, P\u00e9rez de Mendiguren B, Romero M. Erythropoietin plus granulocyte colony-stimulating factor in the treatment of myelodysplastic syndromes. Identification Nomded\u00e9u C, Aventin A. Occurrence of the JAK2 V617F mutation in the WHO provisional refractory thrombocytosis. The Hematology Journal. 2006,91:719-20. Reuters. ImClone soars after setback to rival Amgen drug. March 23, 2007. Ribatti D. A potential role of Leukemia. 2002;16:1890-1. Ribati D, Polimeno G, Vacca Nico B, Lucarelli G, Dammacco F. Correlation of bone marrow angiogenesis and mast cells with tryptase in Ria R, Vacca A. Erythropoietin as an angiogenic factor in gastric carcinoma. Histopathology. 2003;42:246-50. A-Ribatti D, Poliani Longo V, Mangieri D, Nico B, Vacca A. Erythropoietin/erythropoietin receptor system neuroblastoma. Histopathology. 2007;50:636-41. B-Ribatti B, Vacca A, Dammacco F. Erythropoietin/erythropoietin-receptor system is involved in angiogenesis in human hepatocellular carcinoma. Histopathology. 2007;50:591-6. Richards S, Gibbs RA. A truncated receptor cell death: a reanalysis. Science. 1994;264:588-9. Rickles F, Falanga A. Molecular basis for the relationship between thrombosis and cancer. Thromb Res. 2001;102:V215-24. Riely GJ, Politi KA, Miller VA, Pao W. Update on epidermal growth factor receptor mutations in non-small cell lung cancer. Clin Cancer Res. 2006;12(24):7232-41. AR, A, Castoldi G. British Journal of Haematology. 2004;126:501-7. Rivkin S, Green S, Metch B, Cruz A, Abeloff M, Jewell W, Costanzi J, W, Minton receptor-positive Oncol. 1994;12:2078-85. Rizzo J, Lichtin Woolf S, Seidenfeld Bennett C, Cella D, Djulbegovic B, Goode M, Jakubowski A, Lee S, Miller C, Rarick M, Regan D, Browman G, Gordon M. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol. 2002;20:4083-107. Rizzo J, Lichtin Seidenfeld Bennett C, Cella D, Djulbegovic B, Goode M, Jakubowski A, Lee S, Miller C, Rarick M, Regan D, Browman G, Gordon M. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Blood. 2002;100:2303-20. British Journal of Haematology. 1995;91:253-8. Roger R, Fluck R, McMahon A, Raine A. Recombinant erythropoietin increases blood pressure in experimental hypertension and uraemia without change in vascular cytosolic calcium. Nephron.1996;73:212-8. Roger S, Piper J, Tucker B, Raine A, Baker L, Kovacs I. Enhanced platelet reactivity with erythropoietin but not following transfusion in dialysis patients. Nephrol Dial Transplan. 1993;8:213-7. Rogers J, Murgo A, Fontana J, Raich P. Chemotherapy for breast cancer decreases plasma protein C and protein S. J Clin Oncol. 1988;6:276. Rogers S, Russell NH, Morgan AG. Effect of erythropoietin in patients with myeloma. Br J Med. 1990;301:667. Rose E, Abels R, Nelson R, McCullough D, Lessin L. The use of r-HuEpo in the treatment of anaemia related to myelodysplasia (MDS). British Journal of Haematology. 1995;89:831-7. Rosen F, Haraf D, Kies M, Stenson K, Portugal L, List M, Brockstein B, Mittal B, Rademaker A, II study of paclitaxel (1-hour infusion), fluorouracil, hydroxyurea, and concomitant twice daily radiation with or without erythropoietin for advanced head and neck cancer. Clinical Cancer Research. 2003;9:1689-97. Rosenzweig M, Bender CM, Lucke JP, Yasko JM, Brufsky AM. Increased thrombotic events in a clinical trial of erythropoietin (EPO) in metastatic breast cancer. Proc Am Soc J, Yasko J, Brufsky A. The decision to prematurely terminate a trial of R-HuEPO due to thrombotic events. J Pain Symp Manage. 2004;27:185-90. Ross SD, Allen E, Henry DH, Seaman C, Sercus B, Goodnough LT. Clinical benefits and risks associated with epoetin and darbepoetin in patients with chemotherapy-induced anemia: a systematic review of the literature. Clinical Therapeutics. 2006;28:801-31. Rossert J, Eckardt K. 2005;20:1025-28. Runde Aul C, Ebert A, Grabenhorst U, Schneider W. Sequential administration of recombinant human granulocyte-macrophage colony-stimulating factor and human erythropoietin for treatment of myelodysplastic syndromes. European Journal of Haematology. 1995;54:39-45. Rushing DA, Einhorn LH, Wildgust M. Epoetin alfa 40,000 u once weekly significantly improves hemoglobin and quality of life in anemic colorectal cancer patients. Proc Am Soc Clin Oncol. 2003;22:3098. Rytting M, Worth L, N. Hemolytic with cancer. Hematol Oncol Clin Sakai K, Saijo N. Once weekly epoetin beta to increase hemoglobin and improve quality of life in anemic cancer patients receiving chemotherapy: a randomized, double-blind, dose-finding study. Danielson B, Wikstrom B. The pharmacokinetics of recombinant human erythropoietin after intravenous and subcutaneous administration to healthy subjects. Br J E, Karagianidis G, Aravantinos G. Darbepoetin alfa assessment in chemotherapy induced anemia. Journal of Clinical Oncology. 2006;24(18S):18617. Sanders M, Sorba S, Dainiak N. Insulin-like growth factors stimulate erythropoiesis in serum-substituted umbilical cord blood cultures. Experimental Hematology. 1993;21:25-30. Sanders MR, Lu H, Walker F, Sorba S, Dainiak N. The Raf-1 protein mediates insulin-like Tormey D, Gray R. Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol. 1991;9:286-94. Savonije J, Van Groeningen C, Van H, Giaccone G. Early intervention with epoetin-alfa during platinum-based chemotherapy. Journal of Clinical Oncology. 2004;22(14S):8111. Savonije J, van Groeningen C, van A, van Felius C, Wormhoudt L, Giaccone G. Effects of early intervention with epoetin alfa on transfusion requirement, hemoglobin level and survival during platinum-based chemotherapy: Results of a multicenter randomized controlled trial. Eur J Cancer. 2005;41(11):1560-9. Savonije J, van Groeningen C, Wormhoudt L, Giaccone G. Early intervention with epoetin alfa during platinum-based chemotherapy: an analysis of the results of a multicenter, randomized, controlled trial based on initial hemoglobin level. The Oncologist. 2006;11(2):206-16. Savonije J, van Groeningen C, Wormhoudt L, Early Intervention with epoetin alfa during platinum-based chemotherapy: an analysis of quality-of-life results of a multicenter, randomized, controlled trial compared with population normative data. The Oncologist. 2006;11:197-205. Schiffer CA. Clinical issues in the management of patients with myelodysplasia. Hematology. 2006;205-10. Schipper Wolf J, Coppens P, Blijham GH. Recombinant human erythropoietin in patients with myelodysplastic syndromes. Leukemia. 1991;5(5):432-6. Schreiber D, Kapp D. Axillary-subclavian vein thrombosis following combination chemotherapy and radiation therapy in lymphoma. Int J Radiat Oncol Bio Phys.1986;12:391-5. Rossi G, Tomita Colowick A, Glaspy J. Optimizing management of chemotherapy-induced anemia: a combined analysis of data using a darbepoetin frontloading/maintenance approach. Proc Rossi G, Adamson R. A multicenter retrospective cohort study of practice patterns and clinical outcomes of the use of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia. Clinical Therapeutics. Schwartzberg L, Yee L, Senecal F, Charu V, Tomita D, Wallace J, Rossi G. A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer. The Oncologist. 2004;9:696-707. Schwartzberg L, Yee L, Senecal F, Charu V, Tomita D, Rossi G. Darbepoetin alfa (DA) 200 mcg every 2 weeks (Q2W) vs epoetin alfa (Epo) 40,000 U weekly (QW) in anemia patients (pts) receiving chemotherapy (ctx). Journal of Clinical Oncology. 2004;22(14S):8063. Scott S, Boeve T, McCulloch T, Fitzpatrick K, Karnell L. The effects of epoetin alfa on transfusion requirements in head and neck cancer patients: a prospective, randomized, placebo-controlled study. The Laryngoscope. 2002;112:1221-29. Hematology. 2000;7:156-60. Selzer E, Wacheck V, Kodym R. in human melanoma cells. Melanoma Res. 2000;10:421-6. Semrad T, O'Donnell R, Wun T, Chew H, Harvey D, Zhou H, White R. Epidemiology of venous thromboembolism in 9489 patients with malignant glioma. F, Yee L, Gabrail N, Charu V, Tomita D, Rossi G, Schwartzberg L. Treatment of chemotherapy-induced anemia in breast cancer: results of a randomized controlled trial of darbepoetin alfa 200\u00b5g every 2 weeks versus epoetin alfa 40,000U Cancer. 2005;6:446-54. JA, El-Serag HB. The epidemiology of pancreatic cancer in the united states: changes below the surface. Aliment Pharmacol Ther. 2006;24(1):87-94. Shapiro S, Gerson H, Rosenbaum H, and Merchav S. Characterization of Circulating Erythrocytes from Myelodysplastic Patients Treated with Recombinant Human Erythropoietin. Leukemia. 1993;7:1328-33. Sharpe P, Desai Z, Morris T. Increase in mean platelet volume in patients with chronic renal failure treated with erythropoietin. J Clin Pathol. 1994;47:159-61. Shasha D. The negative impact of anemia radiotherapy and chemoradiation outcomes. Seminars in Hematology. 2001;38(3):8-15. Shasha D, Harrison LB. Anemia treatment and the radiation oncologist: optimizing patient outcomes. Oncology. 2001;15(11):1486-96. Shasha D, George M, Harrison L. Once-weekly dosing of epoetin-a increases hemoglobin and improves quality of life in anemic cancer patients receiving radiation therapy either concomitantly or sequentially with chemotherapy. Cancer. 2003;98:1072-79. Shasha D, Homel P, Harrison LB. The additive effect of chemotherapy (CT) on the prevalence and severity of anemia of in cancer patients (pts) receiving curative-intent radiation therapy (RT). Proc Am Soc Clin Oncol. response to extended dosing of epoetin alfa 60,000 U every 2 weeks in anemic cancer patients not receiving therapy: final results. Blood. 2006;108(11):3764. Shasha D, Williams D. Weekly epoetin alfa treatment of anemia in patients with cancer not undergoing therapy. Journal of Supportive Oncology. 2006;4:129-35. Shepherd J, Currie C, Sparling T, Krystal G, A. Erythropoietin Therapy Myelodysplastic Blood. Shinjo K, Takeshita A, Higuchi M, Ohnishi K, Ohno R. Erythropoietin receptor expression on human bone marrow erythroid precursor cells by a newly-devised quantitative Horsman M, Marme D, LoRusso P. Differentiation and Definition of Vascular-Targeted Therapies. Clinical Cancer Research. 2005;11: 416-420. Silberstein PT, Witzig TE, Sloan JA, Mailliard JA, KM, Krook JE, Ghosh C, Steen PD, Loprinzi CL. Weekly erythropoietin for patients with chemotherapy induced anemia: a randomized, placebo-controlled trial in the North Central Cancer Treatment Group. Proc Am Soc Clin Oncol. 2002;21:1422. Singh AK, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. TM, O'Fallon WM, Melton J. Trends in the incidence of deep vein thrombosis and pulmonary embolism. Arch Intern Med. 1998;158:585-93. Silvestris L, Tucci M, Vacca A, Dammacco F. Immunomodulation of T and B cell functions in multiple myeloma patients treated with combined erythropoietin and a-interferon therapy. International Journal of Clinical & Laboratory Research. 1995;25(2):79-83. Silvestris F, Romito A, Fanelli P, Vacca A, Dammacco F. Long-term therapy with recombinant human erythropoietin (rHu-EPO) in progressing multiple myeloma. Annals of Hematology. 1995;70:313-18. Sinclair Knox SJ, Elliott S, Begley CG. Expression and function of erythropoietin receptors in tumors. Cancer. 2007;110(3):477-488. Skilling J, Rogers-Melamed I, Nabholtz, J. An epidemiologic review of anaemia in cancer chemotherapy in Canada. Proc European Conference Clin Cancer M, Ganguly P, Burnell M, Shustik C, Dryer D, McLaughlin M, White D. An epidemiological review of red cell transfusions in cancer chemotherapy. Cancer Prev Control. 1999;3:207-12. Smith RE, Meza L, Tchekmadyian S, Chan Jaiyesimi Fleishman U, Colowick A, Glaspy J. Open-label, phase I/II dose escalation study of NESP in patients with chronic anemia of cancer. Proc Am Soc Clin Oncol. 2001;20:1574. Smith RE, Tchekmedyian S, Richards D, Klarnet Fleishman A, Gayko U, Heatherington A, Glaspy JA. Darbepoetin alfa effectively alleviates anemia in patients with chronic anemia of cancer: efficacy and pharmacokinetic results of a dose-escalation 2002;21:1465. Smith KJ, Bleyer AJ, Little WC, Sane DC. The cardiovascular effects of erythropoietin. Cardiovascular Research. 2003;59:538-48. Smith Jr R, Tchekmedyian N, Chan D, Meza L, Northfelt D, Patel R, Austin M, Colowick A, Rossi G, Glaspy J for the Aranesp 990111 Study Group. A dose- and schedule-finding study of darbepoetin alpha for the treatment of chronic anaemia of cancer. British Journal of Cancer. 2003;88;1851-58. Snady H, Bruckner H, Cooperman A, Paradiso J,Kiefer L. Survival advantage of combined chemoradiotherapy compared with resection as the initial treatment of patients with regional pancreatic carcinoma. An outcomes trial. Cancer. 2000;89(2):314-27. Spiridonidis H, Brinkmann K, Gore K, Tannous RE, Gupta S. Evaluating the \"effectiveness\" of epoetin Pisani Scaramella G, MC. Impact of a new dosing regimen of epoetin alfa on quality of life and anemia in patients with low-risk myelodysplastic syndrome. Annals of Hematology. 2005;84:167-76. Spivak J. Iron and the anemia Oncology (Williston Park). 2002;16(9 Suppl 10):25-33. STAT3 in head and neck squamous cell carcinoma is mediated by the autocrine/paracine stimulation of the interleukin 6/gp130 cytokine system. Cancer Research. 2003;63:2948-56. Stasi R, Brunetti M, S, Conforti M, C, Crescenzi A, Terzoli E, Vecchione A, Pagano A. Response to recombinant human erythropoietin in patients with myelodysplastic syndromes. Clinical Cancer Research. 1997;3:733-9. Stasi R, Brunetti M, Bussa S, Conforti M, Martin LS, La Presa M, Bianchi M, Parma A, Pagano A. Serum levels of tumour necrosis factor-a predict response to recombinant human erythropoietin in patients with myelodysplastic syndrome. Clinical and Laboratory Haematology. 1997;19:197-201. Stasi R, Terzoli E, Amadori S. Recombinant human granulocyte-macrophage colony-stimulating factor plus erythropoietin for the treatment of cytopenias in patients with myelodysplastic syndromes. British Journal Stasi R, Brunetti M, Terzoli E, Amadori S. Sustained response to recombinant human erythropoietin and intermittent all-trans retrinoic acid in patients with myelodysplastic syndromes. Blood. 2002;99:1578-84. Amadori S. Once-weekly dosing of recombinant human erythropoietin alpha in patients with myelodysplastic syndromes unresponsive to conventional dosing. Annals Terzoli E, Amadori S. Darbepoetin alfa for the treatment of anemic patients with low- and intermediate-1-risk myelodysplastic syndromes. Annals of cancer-related anemia H, Gratwohl A, Nissen C, Speck B. High-dose recombinant human erythropoietin for treatment of anemia in myelodysplastic syndromes and paroxysmal nocturnal hemoglobinuria: a pilot study. Experimental Hematology. 1990;18:1204-8. Steensma D, Witzig TE. Does treatment with recombinant human erythropoietin affect the survival of anemic patients with cancer? (commentary). Nature Clinical Practice Oncology. 2005;2(9):444-5. Steensma D, Molina R, Sloan J, Nikecevich D, Schaefer P, Rowland Jr, K, Dentchev T, Novotny P, Tschetter L, Alberts S, Hogan T, Law A, Loprinzi C. Phase III Study of Two Different Dosing Schedules of Erythropoietin in Anemic Patients with Cancer. Journal of Clinical Oncology. 2006; 24: 1079-1089. Stein R, Abels R, Krantz S. Pharmacologic doses of recombinant human erythropoietin in the treatment of myelodysplastic syndromes. Blood. Tsamaloukas A, Weiligmann C, Schmitz S. Evaluation of predictive factors for response to Darbepoetin Alfa (DA): A prospective study. Journal of Clinical Oncology. 2006;24(18S):18514. Stenke L, Wallvik J, Celsing F, Hast R. Prediction of response to treatment with human recombinant erythropoietin in myelodysplastic syndromes. Leukemia. 1993;7(9):1324-7. Steurer M, Sudmeier I, Thromboembolic events in patients with myelodysplastic syndrome receiving thalidomide in combination with darbepoietin-alpha. British Journal of Haematology. 2003;121:101-3. Stohlawetz P, Dzirio L, N. Effects of on platelet reactivity and thrombopoiesis in humans. Blood. 2000;95:2983-9. Stone RM, Bernstein SH, Demetri G, Facklam DP, Arthur K, Andersen J, Aster JC, Kufe D. Therapy with recombinant human erythropoietin in patients with myelodysplastic syndromes. Leukemia Research. 1994;18:769-76. Straus D. Epoeitin Alfa as Seminars in Hematology. 2002;39(suppl 3):25-31. M, Tulpule A, Turner R, Riggs S. Quality-of-life and health benefits of early treatment of mild anemia. Cancer. 2006;107:1909-17. Strauss H, Haensgen G, Dunst J, Hayward C, Koelbl H. Effects of anaemia correction with epoetin beta in patients with advanced cervical cancer and radiochemotherapy. Journal of Clinical Oncology. 2005;23(16S):5121. Sue-Ling H, Johnston D, McMahon M, Philips P. Pre-operative identification of patients at high risk of deep venous thrombosis after elective major abdominal surgery. Lancet. 1986;1:1173-6. Supino-Rosin L, Yoshimura A, Altaratz H, Neumann D. A cytosolic domain of the erythropoietin receptor contributes to endoplasmic reticulum-associated degradation. Eur. J. Biochem. (r-HuEPO) for the treatment of anaemia in patients with multiple myeloma and end-stage renal disease[Letter to the editor]. Nephrology Dialysis Transplantation. 1995;10(12):2374-2375. Svensson A. Application of a New Logic to Old Drugs; Angiogenesis Inhibition in Neuroblastoma. Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine. 2003:1-33. Sweeney P, Nicolae D, Ignacio L, Chen L, Roach III M, Wara W, Marcus K, Vijayakumar S. Effect of subcutaneous recombinant human erythropoietin in cancer patients receiving radiotherapy: final report of a randomized, open-labeled, phase II trial. British Journal of Cancer. 1998;77:1996-2002. Sytkowski A, Feldman L, Zurbuch D. Biological activity and structural stability of N-deglycosylated recombinant human erythropoietin. Biochem Biophys Shinjo K, Higuchi M, Miyawaki S, et al. Quantitative expression of erythropoietin receptor (EPO-R) on acute leukaemia cells: relationships between the amount of EPO-R and CD phenotypes, in vitro proliferative response, the amount of other cytokine receptors and clinical programs. British Journal of Haematology. 2000;108:55-63. Takeshita A, Shinjo R. myelodysplastic syndromes and leukemia. Leukemia & Lymphoma. 2002;43(2):261-4. Tam B, Wei K, Rudge J, Hoffman J, Holash J, Park S, Yuan J, Hefner C, Chartier C, Lee J, Jiang S, Niyak N, Kuypers F, Ma L, Sundram U, Wu G, Garcia J, Schrier S, Maher J, Johnson R, Yancopoulos G, Mulligan R, Kuo C. VEGF modulates erythropoiesis through regulation of adult hepatic erythropoietin synthesis. Nat Med. 200612:793-800. Epub 2006 Jun 25. Tarabay G, Braly P, Baker JJ, Williams D, Waltzman RJ. Treatment of anemia with epoetin alfa 80,000 U QW in cancer patients receiving chemotherapy. Journal of Clinical Oncology. 2004;22(14S):8205. Tarantolo S, Bouda DW. Early results from a novel treatment strategy for chemotherapy-related anemia: epoetin alfa 60,000 U SC QW induction U SC Q2W. Oncology. 2004;22(14S):8204. Tas F, Eralp Basaran M, Sakar Argon A, Bulutiar G, H, Aydiner A, Topuz E. Anemia in oncology practice: relation to diseases and their therapies. Am J Clin Oncol. 2002;25:371-9. Taylor J, McLaren M, Henderson I, Belch J, Stewart W. Prothrombotic effect of erythropoietin in dialysis patients. Nephrol Dial Transplant. 1992;7:235-9. Taylor D, Yoka B, Kusumanto H, Meijer C, Mulder NH, Hospers G. A review on pro-and-antioangiogenic factors as targets of clinical intervention. Pharmacol Res. 2006;53(2):89-103. Ten Bokkel Huinink WW, de Swart C, van Toom D, Morack G, Breed W, Hillen H, van der Hoeven J, Reed N, Fairlamb D, Chan S, Godfrey K, Kristensen G, van Tinteren H, Ehmer B. Controlled multicentre study of the influence of subcutaneous recombinant human erythropoietin on anaemia and transfusion dependency in patients with ovarian carcinoma treated with platinum-based chemotherapy. Medical Oncology. 1998;15:174-82. Terpos NC, X, Viniou N. Prolonged administration of erythropoietin increases erythroid response rate in myelodysplastic syndromes: a phase II trial in 281 patients. British Journal of Haematology. 2002;118:174-80. Thames W, Yao B, Scheifele A, Alley JL. Drug use evaluation (DUE) of darbepoetin alfa in anemic patients undergoing chemotherapy supports a fixed dose of 200 mcg Q2W given every 2 weeks (Q2W). Proc Am Clin Oncol. 2003;22:2196. Thatcher N, De Campos Bell D, Steward W, Varghese G, Morant R, Vansteenkiste J, Rosso E, Stocker H. Epoetin alpha prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer. British Journal of Cancer. 1999;80(3/4):396-402. Thomas GM. Raising hemoglobin: an opportunity for increasing survival? Oncology. 2002;63(suppl 2):19-28. Thomas H, McAdam K, Thomas R, Joffe J, Sugden E, Awwad S. Early intervention with epoetin alpha for treatment of anaemia and improvement of quality of life in cancer patients undergoing myelotoxic chemotherapy. Annals of Oncology. 2002;Vol 13 (Suppl 5):177#653P. Thompson J, Gilliland D, Prchal J, Bennett J, Larholt K, Nelson R, Rose E, Dugan M, GM/EPO MDS Study Group. Effect of recombinant human erythropoietin combined with granulocyte/macrophage colony-stimulating factor in the treatment of patients with myelodysplastic syndrome. Blood. 2000;95(4):1175-9. Throuvalas N, Antonadou D, Boufi M, Lavey R, Malamos N. Erythropoietin decreases Malamos N. Final results of a randomized phase II study evaluating the role of erythropoietin during radiochemotherapy for pelvic tumors. I.J. Radiation Oncology Biology SJ, Ingley E, Klinken SP. Regulation of the erythropoietin receptor and involvement of JAK2 in differentiation of J2E erythroid cells. Cell Growth & Differentation. 1996;7(4):511-20. Tobu O, Fareed D, D, Bansal V, Fareed J. Erythropoietin-induced thrombosis as a result of increased inflammation and inhibitor. R, Raso E. Recombinant human erythropoietin alpha targets intratumoral blood vessels, improving chemotherapy in human xenograft models. Cancer Res. 2005;65:7186-93. Toyoda T, Itai T, Arakawa T, Aoki K, Yamaguchi H. Stabilization of human recombinant erythropoietin through interactions with the highly branched N-glycans. J Biochem (Tokyo). 2000;128:731-7. Trzonkowski Rachon D, Mysliwski A, Rutkowski B. Long-term therapy with recombinant human erythropoietin decreases percentage of CD152+ lymphocytes in primary Preliminary results of amifostine administration in combination with recombinant human erythropoietin in patients with myelodysplastic syndromes. Journal of Experimental and Clinical Cancer Research. 2001;20:35-8. Tsukuda M, Mochimatsu I, Nagahara Kubota A, Furkawa M, Arai Y. Clinical application of recombinant human erythropoietin for treatments in patients with head and neck cancer. Cancer Immunol Immunother. 1993;36:52-56. Tsukuda M, Yuyama S, Kohno H, Kokatsu T, Kokatsu S. Effectiveness of weekly subcutaneous recombinant human erythropoietin administration for chemotherapy-induced anemia. Biotherapy. 1998;11:21-25. Turitto V, Weiss H. Red blood cells: their dual role in thrombus formation. Science. 1980;207:541-43. Turitto VT, Weiss HJ, Baumgartner HR. The effect of shear rate of platelet interaction with subendothelium exposed to citrated blood. Y, Miura Y, Mutoh Y, Fujioka S, Nomura T, Toyama K, Kawato M, Kurokawa K, Yazaki Y, Onozawa Y, Togawa M, Enomoto H, Ogawa M, Ikeda Y, Ohshima T, Aoki Y, Etoh S, Takatsuki K, Araki K. Phase II clinical study of recombinant human erythropoietin on the anemia associated with multiple myeloma. Japan Society of Clinical Hematology. 1993;34(8):919-27. Uppal NP, Griggs J. Incidence, timing and severity of anemia with dose dense breast cancer adjuvant chemotherapy. Journal of Clinical Oncology. 2005;23(16S):8264. Urra JM, de la Torre M, Alcazar R, Peces R. Rapid method for detection of anti-recombinant human erythropoietin antibodies as a new form of erythropoietin resistance. Clinical Chemistry. 1997;43:848-9. USA Today. Cancer Drug Avastin increases risk of stroke, heart attack. 2003. USA Today. 3/11/07. Accessed 3/12/07. Vadhan-Raj S. Recombinant human erythropoietin in other hematopoietic cytokines in attenuating Mirtsching B, Charu V, Terry D, Rossi G, Tomita D, McGuire W. Assessment of hematologic effects and fatigue in cancer patients with chemotherapy-induced anemia given darbepoetin alfa every two weeks. The Journal of Supportive Oncology. 2003;1(2):131-38. Vadhan-Raj S, Schreiber F, Thomas LC, Gandhi J, JJ, Gregory SA, Tomita D, Colowick A. Every-2-week darbepoetin alfa improves fatigue and energy rating scores in cancer patients (pts) undergoing chemotherapy. Proc Am Clin Oncol. 2003;22:2942. epoetin alpha (Procrit) in patients with rectal and gastric cancer undergoing chemo-radiotherapy (CT/RT) followed by surgery: Early termination of the trial due to increased thrombo-embolic events (TEE). Blood. 2004;104(11):#2915. SR, Velloso L, myelodysplastic syndromes and juvenile myelomonocytic leukemia: the Brazilian experience in the past decade. Leukemia Research. 2004;28:933-9. Van den Bosch J, van de werf P, Sleeboom H, Biesma B, Kerkhofs L, Mol J, Ten Velde G, Melissant C. Improvements in anemia management with epoetin alfa-a dutch survey. Journal of Clinical Oncology. 2005;23(16S):8126. Van der Niepen P, Sennesael J, Verbeelen D. r-HuEPO treatment of anemia associated with multiple myeloma and ESRD[Letter to the editor]. Clinical Nephrology. 1993;39(2):113. Van H, T, Kluin Den Ottolander G, Veverstock G, Willemze R, and Fibbe W. Effect of subcutaneously administered human recombinant erythropoietin on erythropoiesis in patients with myelodysplasia. British Journal of Haematology. Guidi S, Saccardi R, Rossi-Ferrini P. Effects of cyclosporine A on erythropoietin production by the human Hep3B hepatoma cell line. Blood. 1993;82(3):978-84. Vannucchi Statello M, Cinotti S, Rossi-Ferrini P. Inhibition of erythropoietin production in vitro by human interferon gamma. British Journal of Haematology. 1994;87:18-23. Vansteenkiste J, Pirker R, Massuti A, J. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. Journal of the National Cancer Institute. 2002;94(16):1211-20. Vansteenkiste J, Poulsen E, Rossi G, Glaspy J. Darbepoetin alfa: impact on treatment for chemotherapy-induced anemia and considerations in special populations. Oncology. 2002;16(10) (suppl):45-55. Vansteenkiste J, Rossi G, Foote M. Darbepoetin alfa: a new approach to the treatment of Expert Opin Biol Ther. Rossi G, R. Darbepoetin alfa in lung cancer patients on chemotherapy: a retrospective comparison of outcomes in patients with mild versus moderate-to-severe anaemia at baseline. Support Care Cancer. 2004;12:253-62. Varan A, Buyukpamukcu M, Kutluk T, Akyuz C. Recombinant human erythropoietin treatment for chemotherapy-related anemia in children. Pediatrics. 1999;103(2):pg # unknown. Varricchio CG, Sloan JA. The need for and characteristics of randomized, phase III trials to evaluate symptom management in patients with cancer. Journal of National Cancer Institute. 2002;94(16):1184-5. Vasu S, Seidler C, Field T, Emani S. Tumor-specific response rates to erythropoietin in chemotherapy-induced anemia in a community practice setting. Journal of Clinical Oncology. 2006;24(18S):18528. Vekeman F, McKenzie RS, Watson S, Mody S, Lefebvre P, Piech CT, Duh MS. Comparison of red blood cell transfusion rates of epoetin alfa and darbepoetin alfa in an inpatient oncology setting. Journal of Clinical Oncology. 2006;24(18S):16002. Vercammen E, Ludwig H, Liu K, Xiu L, Bowers P. Analysis of the effect of body weight on the efficacy and safety of epoetin alfa. Journal of Clinical Oncology. 2005;23(16S):8184. Verhoef G, Ferrant A, Demuynch H. Selleslag D, and Boogaerts M. Recombinant Human Erythropoietin for the Treatment of Anaemia in the Myelodysplastic Syndromes. Second Hove L, Deckers F, Boogaerts MA. Recombinant human erythropoietin for the treatment of anemia in the myelodysplastic syndromes: a clinical and erythrokinetic assessment. Annals GE, Demuynck H, into a myeloproliferative disorder: one or [Letter to the editor]. Leukemia. 1994;8(4):714-715. Verma M. Pancreatic cancer epidemiology. Technology in Cancer Research & Treatment. 2005;4(3):295-301. Vijayakumar S, Roach III M, Wara W, Chan S, Ewing C, Rubin S, Sutton H, Halpern H, Awan A, Houghton A, Quiet C, Weichselbaum R. Effect of subcutaneous recombinant human erythropoietin in cancer patients receiving radiotherapy: preliminary results of a randomized, open-labeled, phase II trial. International Journal of Radiation Oncology, Biology, Physics. 1993;26(4):721-29. Villar A, Martinez J, Fuentes C, Cabezon M, Perez M, Espineira M, Hernandez R, Borque C, Martin J. The use of erythropoietin instead of transfusions to correct anemia in hyperfractioned chemoradiation of advanced head and neck cancer. Proceedings of the 43rd Annual ASTRO Meeting:367. Vinh TT, Lewis BH, Yao B, Yim J. Initial experience with darbepoetin alfa in patients with myelodysplastic syndrome (MDS). Proc Am Soc Clin Oncol. Billups C, Furman W, Rao B, Santana V. Combined use of erythropoietin and granulocyte colony-stimulating factor does not decrease blood transfusion requirements during induction therapy for high-risk neuroblastoma: a randomized controlled trial. J Oncol. 2004;22(10):1886-93. Wagner Granetzny A, Hilejan OM, Krukemeyer MG, Wiedemann GJ. Hb-level stabilization with epoetin alfa in patients with advanced NSCLC undergoing concurrent neoadjuvant chemo-radiation therapy (phase III study). Journal of Clinical Oncology. Wakao H, Chida D, Damen J, Krystal A. A possible involvement of Hast R. Serum erythropoietin (EPO) levels correlate with survival and independently predict response to EPO treatment in patients with myelodysplastic syndromes. European Journal of Haematology. 2002;68:180-6. Walsh J, Bonnar J, Wright F. Study of pulmonary embolism and deep leg vein thrombosis after major gynecological surgery using labeled fibrinogen-phlebography and lung scanning. J Br Commonw. dosing regimens of darbepoetin-alfa for the treatment of patients with anemia during chemotherapy for malignant disease (Correspondence). Cancer. 2004;100(7)1545-6. Waltzman RJ, Fesen M, Justice GR, Croot C, Williams D. Epoetin alfa 40,000 U QW vs darbepoetin alfa 200 mcg Q2W in anemic cancer patients receiving chemotherapy: preliminary results of a comparative trial. Journal of Clinical Oncology. 2004;22(14S):8153. Waltzman R, Croot C, Justice G, Fesen M, Charu V, Williams D. Randomized comparison of epoetin alfa (40,000 U Weekly) and darbepoetin alfa (200 \u00b5g Every 2 Weeks) in anemic patients with cancer receiving chemotherapy. Oncologist. 2005;10 (8):642-50. Ward H, Kurnick J, Pisarczyk M. Serum levels of erythropoietin in anemias associated with chronic infection, malignancies, and primary hematopoietic disease. J Clin Investig. 1971;50:332-5. Ward Vautrin R, Swasdikul D. Effect of serum from myeloproliferative disorders. The Journal of Laboratory and Clinical Medicine. 1971;78(5):849. Weitz I, Israel V, Liebman H. Tamoxifen-associated venous thrombosis and activated protein C resistance due to factor V Leiden. Cancer. 1997;79:2024-7. Welch R, James R, Wilkinson P, Belli F, Cowan R. Recombinent human erythropoietin and platinum-based chemotherapy in advanced ovarian cancer. The Cancer Journal from Scientific American. 1995;1:261-66. Weiss L, Rougier N, Blouin J, Kazatchkine MD, Lhotta K, K\u00f6nig P. Hypocomplementaemia in a newborn caused by transplacental passage maternal autoantibody with C, Baranowski L. Erythropoietin stimulates proliferation of human renal carcinoma cells. Kidney Int. 2000;58:647-57. Wesphal G, Niederberger E, Blum C. Erythropoietin and G-CSF receptors in human tumor cells: expression and aspects regarding functionality. Tumori. 2002;88:150-9. Westphal G, Braun K, Debus J. Detection and quantification of the soluble form of the human erythropoietin receptor (sEpoR) in the growth medium of tumor cell lines and in the plasma of blood samples. Clin Exp Med. 2002;2:45-52. Westphal G, Niederberger E, Blum C, Wollman Y, Knoch TA, Rebel W, Debus J, Friedrich E. Erythropoietin and G-CSF receptors in human tumor cells: expression and aspects regarding functionality. Tumori. 2002;88(2):150-9. Whitaker BI, Sullivan M. The 2005 Nationwide Blood Collection and Utilization Survey Report. http://www.aabb.org/apps/docs/05nbcusrpt.pdf. White R, Chew H, Zhou H, Parikh-Patel A, Harris D, Harvey D, Wun T. Incidence of venous thromboembolism in the year before the diagnosis of cancer in 528,693 adults. Arch Intern Med. 2005;165:1782-7. Wilson C, Lambert H, Scott R. Subclavian and axillary vein thrombosis following radiotherapy for carcinoma K, Horny H, Valent P. Increased Angiogenesis in the Bone Marrow of Patients with Systemic Mastocytosis. American Journal of Pathology. 2002; 160:1639-1645. Winearls C, Oliver D, Pippard M, Reid C, Downing M, Cotes P. Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic dialysis. Lancet. 1986;2:1175-8. Winkelmann J, Penny L, Deaven L, Forget B, Jenkins R. The gene for the human erythropoietin receptor: analysis of the coding sequence and assignment to chromosome 19p. Blood. 1990;76:24-30. Witthuim B, Quelle F, Silvermoine O, Taolin Y, Tang B, Osamu M, Ihle J. F.JAK2 Associates with the Erythropoietin Receptor and is Tyrosine Phosphorylated and Activated following Simulation with Erythropoietin. 1993; 74:227-236. Witzig T, Silberstein P, Loprinzi C, Sloan J, Novotny P, Mailliard J, Rowland K, ALberts S, Krook J, Levitt R, Morton R. Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy. J Clin Oncol. 2005;23:2606-17. World Health Organization (1994). Indicators and strategies for iron deficiency and anemia programs. Report of the WHO/UNICEF/UNU Consultation. Geneva, Switzerland, 6-10 December, 1993. World Health Organization/United Nations University/UNICEF. Iron deficiency anemia, assessment prevention, and control: a guide for program managers. Geneva. WHO. 2001. Wright G, Hanlon P, Amin K, Steenbergen C, Murphy E, Arcasoy M. Erythropoietin receptor expression in adult rat cardiomyocytes is associated with an acute cardioprotective effect for recombinant erythropoietin during ischemia-reperfusion injury. FASEB J. 2004;18:1031-3. Wright J, Ung Y, Julian J, Pritchard K, Whelan T, Smith C, Szechtman R, Roa W, Mulrroy L, G, M. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell disease-related anemia. J Clin Oncol. 2007;25:1027-32. Epub 2007 Feb 20 Wun T, Law L, Harvey D, Sieracki B, Scudder S, Ryu J. Increased incidence of symptomatic venous thrombosis in patients with cervical carcinoma treated with concurrent chemotherapy, radiation, and erythropoietin. Cancer. 2003;98:1514-20. Wurnig C, Windhager R, Schwameis E, Kotz Stockenhuber F, Kurz R. Prevention of chemotherapy-induced anemia by the use of erythropoietin in patients with primary malignant bone tumors (A double-blind, randomized, phase III study). Transfusion. 1996;36:155-59. Xia K, Mukhopadhyay N, Inhorn R, Barber D, Rose P, Lee R, Narsimhan R, D'Andrea A, Griffin J, Roberts T. A. Okamoto Y, Okuno Y, Nakajima T, Kusumi F, Takakuwa H, Matsusue S. Treatment results of chemo-radiotherapy for clinical stage I (T1N0M0) esphogael carcinoma. I.J. Radiation Oncology Biology Physics. 2004;60(1):S300. Yasuda Y, Masuda S, Chikuma M, Inoue K, Nagao M, Sasaki R. Estrogen-dependent production of erythropoietin in uterus and its implication in uterine angiogenesis. J Biol Chem. 1998;273:25381-7. Yasuda Y, Musha T, Tanaka H. Inhibition of erythropoietin signaling destroys xenografts of ovarian and uterine cancers in nude mice. Br J Cancer. 2001;84:836-43. Yasuda Y, Fujita Y, Masuda S, Musha T, Ueda K, Tanaka H, Fujita H, Matsuo T, Nagao M, Sasaki R, Nakamura Y. Erythropoietin is involved in growth and angiogenesis in malignant tumors of female reproductive organs. Carcinogenesis. 2002;23:1797-805. Yasuda Y, Fujita Y, Matsuo T. Erythropoietin regulates Kavakli K. A single institutional experience: is epoetin alfa effective in anemic children with cancer? Hematology Oncology. 2004;21:1-8. Y, and Okuma M. Serial changes in endogenous erythropoietin levels in patients with myelodysplastic syndromes and aplastic anemia undergoing erythropoietin treatment. Annals Zallinger-Thurn Krainer C, Leodolter S, Zielinski CC. Initial hemoglobin levels as Soc J, McGlave P, Banisadre M, Ash R. Studies on the liver to kidney switch of erythropoietin production. J. Clin. Invest. 1981;67:1183-8. Zeigler ZR, Jones D, Rosenfeld CS, Shadduck RK. Recombinant human erythropoietin (rHuEPO) for treatment of myelodysplastic syndrome. Stem Cells. 1993;11:49-55. Zhang W, Gordon M, Lenz H. Novel approaches to treatment of advanced colorectal cancer with anti-EGFR monoclonal antibodies. Ann Med. 2006;38:545-51. Zhu Y, D'Andrea AD. The molecular physiology of erythropoietin and the erythropoietin receptor. Curr Opin Hematol. 1994;1(2):113-8. Zou S, Fujii K, Johnson S, Spencer B, Washington N, Iv EN, Musavi F, Newman B, Cable R, Rios J, Hillyer KL, Hillyer CD, Dodd RY. Prevalence of selected viral infections among blood donors deferred for potential risk to blood safety. Transfusion. 2006;46:1997-2003. Zwezdaryk K, Coffelt S, Figueroa Y, Liu J, Phinney LaMarca H, Florez L, Morris C, Hoyle G, Scandurro A. Erythropoietin, a hypoxia-regulated factor, elicits a "}